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Abstract  
Epigenetic processes that regulate gene expression, such as DNA methylation (DNAm), have 
been linked to individual differences in physical aggression. Yet, it is currently unclear 
whether: (i) DNAm patterns in humans associate with physical aggression independently of 
other co-occurring psychiatric and behavioral symptoms; (ii) whether these patterns are 
observable across multiple tissues; and (iii) whether they may function as a causal vs non-
causal biomarker of physical aggression. Here, we used a multi-sample, cross-tissue design to 
address these questions. First, we examined genome-wide DNAm patterns (buccal swabs; 
Illumina 450k) associated with engagement in physical fights in a sample of high-risk youth 
(n=119; age=16-24 years; 53% female). We identified one differentially methylated region 
in DRD4, which survived genome-wide correction, associated with physical aggression above 
and beyond co-occurring symptomatology (e.g. ADHD, substance use), and showed strong 
cross-tissue concordance with both blood and brain. Second, we found that DNAm sites 
within this region were also differentially methylated in an independent sample of young 
adults, between individuals with a history of chronic-high vs low physical aggression 
(peripheral T cells; ages 26–28). Finally, we ran a Mendelian randomization analysis using 
GWAS data from the EAGLE consortium to test for a causal association of DRD4 
methylation with physical aggression. Only one genetic instrument was eligible for the 
analysis, and results provided no evidence for a causal association. Overall, our findings lend 
support for peripheral DRD4 methylation as a potential biomarker of physically aggressive 
behavior, with no evidence yet of a causal relationship.  
 
Keywords: DNA methylation; physical aggression; DRD4; externalizing problems; 
replication; Mendelian randomization 
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Introduction 
Physical aggression is a highly conserved trait across many species that serves adaptive 
functions for promoting fitness (Nelson & Trainor, 2007). In humans, however, chronic 
physical aggression (e.g. physically destructive, violent and injurious behavior) is a hallmark 
of several psychiatric disorders, and accounts for significant morbidity, mortality, and societal 
cost worldwide (Waters et al., 2004). Physical aggression features as a diagnostic criterion for 
conduct disorder (CD), intermittent explosive disorder (IED) and antisocial personality 
disorder (ASPD) based on the DSM-5 (APA, 2013). Furthermore, physically aggressive 
behavior is overrepresented in individuals affected by other psychiatric disorders, such as 
autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), substance use 
disorders and schizophrenia (e.g. Hamshere et al., 2013; Krueger, Markon, Patrick, Benning, 
& Kramer, 2007; Manchia & Fanos, 2017).  Importantly, longitudinal studies indicate that 
chronic physical aggression in childhood and adolescence predict a wide range of maladaptive 
outcomes in adulthood (Kim-Cohen et al., 2005). Together, this evidence points to physical 
aggression as a behavioral risk marker for broader psychopathology (Sanislow et al., 2010).   
Research to date suggests that individual differences in physical aggression levels 
stem from the complex interplay of genetic and environmental influences. Twin and adoption 
studies have found that around half of the variance in physical aggression is attributable to 
genetic factors (Tuvblad & Baker, 2011) – with higher heritability estimates observed for 
physical aggression that is severe, chronic and pervasive across settings (Waltes, Chiocchetti, 
& Freitag, 2015). Consistent with these findings, molecular genetic studies have reported 
associations between common genetic polymorphisms and physically aggressive behavior, 
focusing mainly on candidate genes involved in dopaminergic and serotonergic 
neurotransmission (esp. MAOA, COMT, 5HTT, and DRD4; Fernàndez-Castillo & Cormand, 
2016; Vitaro et al., 2012) as well as hormonal regulation (e.g. AR, OXTR, AVP; Veroude et 
al., 2016). While only suggestive associations with individual single nucleotide 
polymorphisms (SNPs) have been identified by genome-wide studies, total SNP heritability 
has been found to account for substantial variance in aggressive behavior (measured globally), 
providing further evidence for genetic effects (10-54% across different population-based 
cohorts; Pappa et al., 2015). In addition to genetic predispositions, epidemiological and 
clinical studies have identified numerous environmental risk factors for pathological physical 
aggression, including childhood abuse and neglect, family dysfunction, low socioeconomic 
status, and violence exposure (Chistiakov & Chekhonin, 2017). Together, these factors are 
thought to co-act with genetic vulnerabilities to modulate propensity for physical aggression 
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(Tremblay, 2015). At present, however, little is known about the biological mechanisms 
through which these genetic and environmental inputs become translated into phenotypic 
variation.  
In recent years, epigenetic processes that regulate gene expression, such as DNA 
methylation (DNAm), have emerged as a potential mechanism of interest. DNAm modulates 
transcriptional activity via the addition of a methyl group to DNA base pairs, primarily in the 
context of cytosine-guanine (CpG) dinucleotides (Jaenisch & Bird, 2003). Studies have shown 
that DNAm patterns are: (i) under significant genetic control – as evidenced by the discovery 
of a large number of methylation quantitative trait loci (mQTLs; Gaunt et al., 2016); and (ii) 
sensitive to environmental signals, including nutritional, chemical, physical and psychosocial 
exposures occurring in utero and beyond (Szyf & Bick, 2013). In turn, DNAm patterns have 
been shown to associate with a broad range of psychiatric, physical and behavioral 
phenotypes, including externalizing spectrum symptoms such as conduct problems, ADHD, 
and substance use (Barker, Walton, & Cecil, 2018; Klengel & Binder, 2015). Consequently, 
DNAm shows promise as a mechanism through which genetic and environmental factors 
interface, shaping trajectories of neurodevelopment, health and behavior across the lifespan 
(Tremblay & Szyf, 2010).  
Thus far, only a handful of studies in humans have examined DNAm patterns 
associated with physical aggression. These studies were mainly based on data from young 
adults (DNA extracted from white blood cells at age 26-28yrs), who were recruited as part of 
the Montreal Longitudinal and Experimental Study (MLES; Boisjoli, Vitaro, Lacourse, 
Barker, & Tremblay, 2007) and the Quebec Longitudinal Study of Kindergarten Children 
(QLSKC; Rouquette et al., 2014) and who were classified as following either a chronic vs low 
trajectory of physical aggression during childhood (ages 6-15yrs; Broidy et al., 2003). Using 
both targeted gene (Provençal, Suderman, Caramaschi, et al., 2013; Dongsha Wang et al., 
2012) and epigenome-wide (Guillemin et al., 2014; Provençal et al., 2014) approaches, these 
studies have reported group differences in DNAm across a large number of gene promoters. 
Of interest, several of these genes related to biological processes that have been previously 
implicated in physical aggression, including monoamine neurotransmission, neuroendocrine 
function and inflammatory response (Provençal, Booij, & Tremblay, 2015). Besides this 
sample, one other study (van Dongen et al., 2015) based on a general population sample of 
over 2000 adult twins examined epigenome-wide associations between DNAm (extracted 
from whole blood at mean age = 36.4yrs) and a global measure of aggressive behavior (i.e. 
not specifically related to physical aggression, but also including social and verbal 
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aggression). None of the DNAm sites were found to associate with aggressive behavior after 
multiple correction, which the authors suggested may have been due to low rates of more 
severe forms of aggression (i.e. physical aggression). However, a gene ontology analysis 
identified significant enrichment for genes involved in a range of central nervous system 
processes. As would be expected for brain-based phenotypes, epigenetic alterations in genes 
involved in neural function have also been observed in psychiatric disorders that feature 
aggression as a diagnostic criterion, such as childhood disruptive behavior disorders (Barker, 
et al., 2017; Cecil et al., 2017), intermittent explosive disorder (Montalvo-Ortiz, Zhang, Chen, 
Liu, & Coccaro, 2018) and antisocial personality disorder (Beach, Brody, Todorov, Gunter, & 
Philibert, 2011; Checknita et al., 2015). 
Despite these promising findings, research on DNAm and physical aggression in 
humans has been limited in a number of important ways. One first limitation relates to 
comorbidity. Individuals with high physical aggression often present with elevated 
symptomatology across a range of psychiatric and behavioral domains, such as hyperactivity, 
callous-unemotional traits, emotional problems, and substance use, which have also been 
associated with altered DNAm patterns (Barker, Walton, & Cecil, 2018). Because these are 
not typically examined in the extant literature, however, it remains unclear whether the 
identified DNAm patterns may be unique to physical aggression, shared with – or confounded 
by – other symptom domains. Relatedly, little is known about the extent to which these 
epigenetic patterns may reflect environmental risk factors for physical aggression (rather than 
aggression per se), such as childhood maltreatment and deprivation. Examining these 
associations is crucial in order to characterize more precisely the epigenetic ‘signature’ of 
physically aggressive behavior, and its relationship to other common correlates of – and risk 
factors for – physical aggression.  
A second limitation in the extant literature relates to tissue specificity. To date, studies 
on physical aggression in humans have been based entirely on DNA extracted from blood 
cells, as it is not possible to measure in vivo DNAm levels directly from the brain. This is 
problematic, given that DNAm patterns can vary substantially between tissues and cell-types 
(Smith et al., 2015). As such, it remains unclear to what extent DNAm patterns associated 
with physical aggression in blood may reflect those in the brain – likely the most relevant 
organ for the study of aggressive behavior (Bakulski, Halladay, Hu, Mill, & Fallin, 2016). 
Establishing peripheral-central nervous system (CNS) concordance in DNAm is all the more 
important given that existing findings in blood point to the involvement of neural-related 
genes. Furthermore, no study to date has examined associations between physical aggression 
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and DNAm in buccal cells, another easily accessible peripheral tissue that has recently been 
found to correlate more strongly with brain tissue than blood (Smith et al., 2015). To this end, 
cross-tissue designs are necessary in order to gauge the utility of peripheral DNAm as a 
potential marker of brain-based behavioral phenotypes, such as physical aggression (Bakulski 
et al., 2016).  
Finally, there has been a paucity of investigation regarding the potential mechanistic 
role of peripheral DNAm in physical aggression. In other words, based on associations alone, 
it is not currently possible to establish whether DNAm acts as causal or non-causal marker of 
physical aggression. Addressing this question bears important implications for informing 
research and clinical practice. On the one hand, DNAm marks need not to exert a causal 
influence in order to show potential utility as biomarkers – so long as they are robustly and 
reliably associated with a phenotype of interest. This is well exemplified in oncology, where 
non-causal DNAm patterns are already being used in the clinic as biomarkers for cancer 
detection, prognosis and even treatment response (Ladd-Acosta & Fallin, 2015). In the case of 
physical aggression, non-causal biomarkers could show utility in a number of different ways. 
First, non-causal biomarkers that reliably index increased risk for developing pathological 
aggression may be used, for example, to build more accurate predictive models. In turn, such 
models may help early detection and prevention via allocation of resources towards 
improvement of risk trajectories (e.g. preventive interventions to enhance mental health, 
social communication, emotional and behavioral regulation, etc.). Second, non-causal 
biomarkers that are associated with response to treatment for pathological aggression (e.g. 
anger management, dialectical behavior therapy, etc), may help to inform decisions about 
treatment formulation. On the other hand, a causal effect is important in order to shed light on 
etiological pathways and to identify promising intervention targets. Indeed, interventions 
designed to modify DNAm marks (e.g. via pharmacological treatment) will be unlikely to 
have an effect on physical aggression unless these DNAm marks lie along the causal pathway 
(Szyf, 2015). Advanced inference methods, such as Mendelian randomization (MR), represent 
one important tool for testing causality. MR involves the use of genetic information to 
minimize confounding common in observational research and strengthen causal inference 
about the effect of an exposure on an outcome (Davey Smith & Hemani, 2014). While this 
method has been previously adapted to epigenetic markers (Relton & Davey Smith, 2012; 
Caramaschi et al., 2017; Richardson et al., 2018) and utilized to examine causality between 
peripheral biomarkers and a range of psychiatric outcomes (Prins et al., 2016; Pingault, Cecil, 
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Murray, Munafo, & Viding, 2016;), it has yet to be utilized to clarify the nature of the 
observed relationship between DNAm and physical aggression. 
The present study 
In light of the aforementioned gaps in the literature, the present study had three main aims. 
First, we used a hypothesis-free, genome-wide approach to examine DNAm patterns (DNA 
extracted from buccal swabs) associated with physically aggressive behavior, measured as 
engagement in physical fights over the past year, based on data from a community sample of 
high-risk youth. Second, we sought to comprehensively characterize the properties of 
aggression-associated DNAm patterns, including: (i) unique vs shared associations with 
commonly co-occurring psychiatric and behavioral symptoms; (ii) relation to genetic and 
environmental factors; (iii) cross-tissue concordance with blood and brain using publicly 
available resources (Edgar, Jones, Meaney, Turecki, & Kobor, 2017; Hannon, Lunnon, 
Schalkwyk, & Mill, 2015; Smith et al., 2015); and, (iv) independent replication in adults with 
a chronic vs low history of physical aggression – the sample upon which most epigenetic 
studies of aggression to date have been based (Guillemin et al., 2014; Provençal et al., 2014).  
We considered DNAm loci to be potential biomarkers if they showed associations with 
physical aggression that were replicable and robust to multiple sensitivity analyses, based on 
the broad definition of a biomarker as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathologic processes or biological 
responses to a therapeutic intervention” (Biomarkers Definition Working Group, 2001).  
Finally, we explored the causal nature of the identified associations using Mendelian 
randomization based on GWAS data from the Early Genetics and Lifecourse Epidemiology 
consortium (EAGLE; Pappa et al., 2015), in order to provide preliminary data as to the 
potential role of DNAm patterns as a causal vs non-causal biomarker of physical aggression. 
Given the lack of prior evidence in this area, we did not have a-priori hypotheses about 
causality in the association between peripheral DNA methylation and physical aggression. As 
such, our application of MR was guided by the epigenome-wide association analysis and 
should be considered as hypothesis-generating (Evans & Davey Smith, 2015). 
 
Materials and Methods 
Participants 
The current sample was recruited as part of a larger cross-sectional study examining the 
influence of early adversity on youth outcomes (n = 204, age range = 16-24 years). Youth 
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from deprived areas of London were recruited through multiple channels including inner-city 
colleges, internet websites, and a charity providing services to vulnerable youth, typically via 
self-referral. The study was carried out in accordance with the latest version of the 
Declaration of Helsinki. All procedures were approved by the UCL Research Ethics 
Committee (ID No: 2462/001) and participants provided informed consent prior to 
participation, after the nature of the procedures had been fully explained. Full details of the 
sample and study procedures are available elsewhere (Cecil et al., 2016; Cecil, Viding, 
Barker, Guiney, & McCrory, 2014) 
 The present analyses only included participants with complete data on DNAm and 
self-report engagement in physical fights (n = 119). This subsample was 53% female, 
ethnically diverse (49% White, 33% Black, 12% Other, 6% Asian) and at high-risk of 
adversity, with 68% of youth reporting experiences of childhood maltreatment. This 
subsample was comparable to the full sample in terms of sociodemographic characteristics 
and exposure to adversity. In addition to self-report measures, informant reports were 
available for 80% of the subsample (n = 95), whereby an external informant (schools: 
teacher; charity: key worker) who knew each participant well completed a questionnaire 
booklet about the young person’s emotional and behavioral function.  
Measures 
DNA methylation. DNA was extracted from buccal swabs (representing a mixture of 
buccal epithelial cells and leukocytes) using procedures described in Freeman et al. (2003). 
500ng of high molecular weight DNA was subjected to sodium bisulfite conversion using the 
EZ-DNA methylation kit (Zymo Research, Orange, CA, USA) using the manufacturers 
standard protocol. DNAm was quantified using the Illumina HumanMethylation450 
BeadChip (Illumina, USA) with arrays scanned using an Illumina iScan (software version 
3.3.28). Samples were run in a single batch (i.e. bisulfite treatment and processing run at the 
same time across two plates side by side). To account for potential chip and position effects, 
we randomized sample chip allocation and placement on the chip. Furthermore, surrogate 
variable analysis was applied as a sensitivity step to minimize the influence of unmeasured 
sources of confounding (see results section).  Initial data quality control was conducted using 
GenomeStudio (version 2011.1) to determine the status of staining, extension, hybridization, 
target removal, bisulfite conversion, specificity, non-polymorphic and negative controls. 
Probes that survived this stage were checked for concordance between their reported and 
predicted sex and then quantile normalised using the dasen function within the waterRmelon 
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package (waterRmelon_1.0.3; Pidsley et al., 2013) in R. Probes were removed if they were 
cross-reactive, polymorphic, used for sample identification on the array, had a SNP at the 
single base extension with a minor allele frequency larger than 5% (i.e. common 
polymorphisms;  Chen et al., 2013; Price et al., 2013), leaving a total of 413,510 probes in our 
sample. DNAm levels are indexed by beta values (ratio of methylated signal divided by the 
sum of the methylated and unmethylated signal, M/M+U).  
Engagement in physical fights. Engagement in physical fights was assessed via a 
self-reported item adapted from the Youth Risk Behavior Survey (YRBS; Eaton et al., 2008). 
The item specifically asked about the frequency of being in physical fights over the past year 
(“During the past 12 months, how many times were you in a physical fight?”). The item was 
rated on a 4-point scale, with 0 = ‘0 times’, 1 = ‘1 time’, 2 = ‘2-5 times’, and 3 = ‘5+ times’.  
Environmental risks. Childhood maltreatment was measured using the total score of 
the 28-item, self-report Childhood Trauma Questionnaire (CTQ; Bernstein & Fink, 1998; α = 
.84), which assesses experiences of abuse and neglect “while growing up”. Community 
violence exposure (CVE) over the past year was measured using the self-report Children’s 
Report of Exposure to Violence (CREV; Cooley, Turner, & Beidel, 1995). The CREV records 
frequency of exposure to different forms of violence, including fights, robberies, shootings, 
and killings. A total CVE score was obtained by summing the three subscales of hearing 
about, witnessing and directly experiencing community violence (α = .79–.89). Neighborhood 
Deprivation was measured using the postcode-derived Index of Multiple Deprivation (IMD; 
Noble, Wright, Smith, & Dibben, 2006) score, an aggregate measure based on population 
census data that encompasses multiple indicators of neighborhood deprivation, spanning: (i) 
income; (ii) employment; (iii) health and disability; (iv) education skills and training; (v) 
barriers to housing and services; (vi) crime; and, (vii) living environment. Higher values 
indicate more severe childhood maltreatment, CVE, and neighborhood deprivation.  
Psychiatric and behavioral correlates of physical aggression. We assessed multiple 
domains of individual functioning that have previously been associated with physical 
aggression. Self-reported substance use was measured via the Alcohol Use Disorders 
Identification Test (AUDIT; Saunders, Aasland, Babor, de la Fuente, & Grant, 1993) and the 
Drug Use Disorders Identification Test (DUDIT; Berman, Bergman, Palmstierna, & Schlyter, 
2003). The AUDIT and DUDIT include 10 (α = .82) and 11 (α = .90) items respectively, 
measuring substance use, harmful use and symptoms of dependence. External informants (i.e. 
teachers/key workers) completed the DSM-based Adolescent Symptom Inventory (ASI-4; 
Gadow & Sprafkin, 1998) to assess symptoms of emotional and behavioral disorders, 
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including generalized anxiety disorder (GAD), major depressive disorder (MDD), attention-
deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), conduct disorder 
(CD), and antisocial personality disorder (ASPD). Each scale contained between 7 and 9 
items (α = .85 – .96). In addition to examining each symptom domain separately, the GAD 
and MDD subscales were combined into an overall score of internalizing problems (α = .93), 
whereas the ODD, CD, ASPD and ADHD subscales were combined into an overall score of 
externalizing problems (α = .97; Cecil et al., 2014). External informants also rated prosocial 
behavior via the Strength and Difficulties Questionnaire prosocial behavior subscale (SDQ; 
Goodman, 1997; α =.76) as well as callous-unemotional (CU) traits via the Inventory of 
Callous-Unemotional Traits (ICU; Frick, 2004; α =.79).  
Data Analysis 
All analyses were performed in R (version 3.0.1), controlling for sex, age and self-reported 
ethnicity (coded as a dummy variable) to account for potential confounding effects (Liang & 
Cookson, 2014). The analysis proceeded in three steps: 
Step 1: Are DNAm patterns in buccal cells associated with engagement in 
physical fights in a sample of high-risk youth? We addressed this question by using both 
probe- and region-level analyses. In probe-level analyses, we ran an epigenome-wide 
association analysis (EWAS) using the IMA package (Dan Wang et al., 2012) to identify 
differentially methylated probes (DMPs). DMPs were considered to be genome-wide 
significant if they passed a False Discovery Rate (FDR) correction of q ≤ .05. To identify 
enriched biological pathways, DMPs with a p ≤ .001 were analyzed further using an 
optimized gene ontology (GO) method that corrects for multiple potential confounds, 
including background probe distribution and gene size (for a full description, please refer to 
the Supplementary Methods). As a complement to the probe-level analysis, we also used 
two independent regional approaches with default settings – Comb-p (Pedersen, Schwartz, 
Yang, & Kechris, 2012) and DMRcate (Peters et al., 2015) – to locate wider differentially 
methylated regions (DMRs). DMRs were only considered significant if they survived multiple 
correction across both methods. Relevant DNAm markers were then characterized further by: 
(i) testing associations with environmental risks and domains of individual functioning known 
to correlate with physical aggression; and (ii) investigating cross-tissue concordance with both 
blood and brain, based on independent published data (Hannon et al., 2015; Smith et al., 
2015). Further details regarding these cross-tissue resources are provided in the results section 
below.  
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Step 2: Are these markers differentially methylated in blood samples drawn from 
young adults with a history of chronic vs low physical aggression? Next, we examined 
whether the DNAm markers that met genome-wide significance in Step 1 were differentially 
methylated in peripheral leukocytes drawn from an independent sample of 38 young adults 
(Guillemin et al., 2014). Participants were identified as either following a chronic (CPA; n= 
13; 38% female) or low (LPA; n= 25; 54% female) trajectory of physical aggression during 
childhood, based on prospective, longitudinal data (Broidy et al., 2003). DNAm from 
peripheral T cells was extracted at ages 26-28 years and quantified using the Illumina 450k 
array. Due to the low volume of available DNA for Illumina 450k quantification, the 38 
samples were originally pooled into 12 samples. Each sample comprised the same amount of 
DNA from 2 to 4 individuals of the same sex creating 6 samples for the CPA group (3 pools 
for men CPA and 3 pools for women CPA) and 6 samples for the LPA group (3 pools for men 
LPA and 3 pools for women LPA). For full details about the sample as well as the processing 
of the DNAm data, see (Guillemin et al., 2014). All participants were of Caucasian ethnicity 
and both groups were matched for sex; consequently, ethnicity and sex were not included as 
covariates. In the analyses, group differences in DNAm were tested using linear regression 
models, correcting for age. All regressions were bootstrapped 10,000 times (boot package), 
and bias-corrected 95% confidence intervals (CI) were derived using the adjusted bootstrap 
percentile method (BCa; boot.ci function). Rather than evaluating replication based on FDR-
corrected p-values – which can be unreliable in small samples due to bias in the estimates and 
standard errors – we used multiple other indicators that are less sensitive to sample size, 
namely the direction and magnitude of effects as well as the bias-corrected bootstrapped 95% 
confidence intervals. Bootstrapping is a nonparametric resampling simulation method that 
enables to address some of the issues of asymptotic inference by performing bias-adjustment 
and controlling for the proportion of Type I errors based on the empirical distribution of the 
data (Pace, 2012). Associations with bootstrapped confidence intervals that did not cross zero 
were considered significant. 
Step 3: Do these associations potentially reflect causal pathways? As a final step, 
we tested the potential causal effect of the identified DNAm markers on aggressive behavior 
using Mendelian randomization. MR is a technique that uses genetic variants as robust 
instrumental variables, in order to strengthen causal inferences about the effect of an exposure 
on an outcome while minimizing potential confounding (Pingault et al., 2016). Full details of 
the MR analysis are provided in the Supplementary Methods. Briefly, the MR analysis 
involved (i) selecting genetic instruments (i.e. SNPs) for the identified DNAm markers using 
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the mQTLdb database (http://www.mqtldb.org; Gaunt et al., 2016); (ii) extracting summary 
statistics about their association with aggressive behavior, based on recently published GWAS 
data from the EAGLE consortium (Pappa et al., 2015); and (iii) running the MR analysis 
based on the results from the mQTLdb search (i.e. SNP  DNAm) and the GWAS data (i.e. 
SNP  physical aggression) using the TwoSampleMR package in R, available as part of the 
MR-Base platform (www.mrbase.org; Hemani et al., 2016).  
 
Results 
Response frequencies for engagement in physical fights over the past year were as follows: N0 
times = 88, N1 time = 16, N2-5 times = 11, N5+ times = 4. This variable did not correlate with age 
(Spearman’s rho; r = .03, p = .67) or differ by sex (F(1) = .64, p = .42). However, it was 
associated with self-reported ethnicity (F(3) = 4.62, p = .004), with Black ethnicity 
associating with a higher number of fights.  
Step 1: Epigenome-wide associations between buccal cell DNAm and engagement in 
physical fights 
Probe-level analysis. The results of the probe-level EWAS are depicted in Table 1. 
Overall, inspection of the Q-Q plot indicated little evidence of inflation (Figure S1), which 
was confirmed using the Bayesian method in the Bacon R package (van Iterson et al., 2017; 
Figure S2). Four DMPs were found to meet a genome-wide threshold of significance (q ≤ 
.05; bolded in Table 1; see Figure S1 for the Manhattan plot and scatterplots for each DMP): 
(i) cg21217577, located in the body of the TRH gene, a key member of the hypothalamic–
pituitary–thyroid axis involved in hormonal regulation (Yarbrough, Kamath, Winokur, & 
Prange, 2007); (ii) cg11107262 in the body of GAK, a gene involved in cellular function 
(Shimizu, Nagamori, Yabuta, & Nojima, 2009); (iii) cg27349081, annotated to the promoter 
region of RIC3, a molecular chaperone modulating the expression of nicotinic acetylcholine 
and serotoninergic 5-HT3 receptors (Castillo et al., 2005); and (iv) cg27331554 located in the 
body of CYFIP2, a component of the WAVE1 complex implicated in immune function and 
BDNF-NTRK2 signaling (Xu, Fu, Zhu, & Liu, 2016). Also listed in Table 1 are suggestive 
DMPs that did not meet genome-wide correction (q > .05). Of interest, five of these were 
located in the gene body of the dopamine receptor gene DRD4, one of the most extensively 
studied candidate genes for physical aggression and related externalizing problems 
(Fernàndez‐Castillo & Cormand, 2016). Furthermore, a number of additional DMPs were 
annotated to neurotransmitter and neuroendocrine genes, including other dopaminergic 
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(COMT), serotonergic (GPM6B), glucocorticoid (SGK1) and thyroid hormone (TXNRD2, 
TNX2, FDX1) pathway genes. More broadly, our GO analysis indicated enrichment for a 
range of biological processes, including axon guidance (p = 1.66E-09), hormone metabolic 
processes (p = 1.13E-08), behavioral regulation (p = 8,86E-07), dopamine receptor signaling 
(p = 1.51E-06), cytokine secretion (p = 6.73E-06), and drug response (p = 1.17E-04; Table 
S1).  As a control, we reran the GO analysis with a comparable number of randomly selected 
CpG sites and found only a chance-level overlap in identified terms (<5%).  
Region-level analysis. The Comb-p analysis identified two genome-wide significant 
regions (DMRs), both of which were annotated to the DRD4 gene. Consistent with the probe-
level analysis above, these two regions were adjacent to one another (spanning a total of 
603bp) and encompassed the five DMPs listed in Table 1 – all of which were hypo-
methylated in relation to physical aggression, following a dose-response gradient (see Figure 
S3 for scatterplots). The first region included probes cg03909863, cg01616529, and 
cg05717871 (chromosomal coordinates: start = 638404, end = 638507; Sidak-corrected 
regional p = 1.09E-07), whereas the second region included probes cg11335335 and 
cg07212818 (chromosomal coordinates: start = 637885, end = 638076; Sidak-corrected 
regional p = 1.62E-04). Overall, these five probes showed moderate-to-high intercorrelations 
(r = .47 – .79), with 74% of shared variance between them explained by a single principal 
component (eigenvalue = 3.72, princomp function; see Figure S4). Importantly, results from 
Comb-p were confirmed using the DMRcate package, in which the same five probes formed 
the only DMR to survive genome-wide correction (chromosomal coordinates: start = 637885, 
end = 638507; q = 6.61E-15, Stouffer-corrected p = .01).  Consequently, these five probes 
were examined as a single region in subsequent analyses.  
********************************** Table 1********************************* 
Follow-up analyses: characterizing DRD4 methylation. In light of the above 
findings, we carried out a number of follow-up analyses to better characterize patterns of 
DRD4 methylation in this sample.  
1. Associations between the DRD4 DMR and correlates of physical aggression. First, 
we examined associations with known environmental and phenotypic correlates of physical 
aggression. Table 2 shows Spearman correlations for (i) the engagement in fights variable, 
and (ii) the five CpG probes contained in the DMR, as well as the principal component 
capturing shared variance between them. As expected, engagement in physical fights was 
significantly correlated with all variables, associating with greater exposure to adversity, more 
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severe psychiatric symptoms (especially externalizing problems), higher substance use and 
CU traits as well as lower prosocial behavior. All probes contained in the DMR were 
negatively associated with engagement in physical fights (i.e. individuals with lower DNAm 
in these probes engaged in a higher number of fights). Associations with environmental risks 
were generally weak, with lower DNAm levels associating significantly with greater 
community violence exposure and neighborhood deprivation, but not childhood maltreatment. 
With regards to co-occurring outcomes, lower DNAm across sites associated most strongly 
with higher self-reported drug use, informant-rated CU traits and low prosocial behavior, as 
well as externalizing (especially CD and ASPD) – but not internalizing – psychiatric 
symptoms. DNAm levels in this region remained significantly associated with engagement in 
physical fights even after adjusting for all domains of individual functioning (spearman 
correlation with DMR principal component using the ppcor package: (i) bivariate: r = -.39, p 
= 1.10E-05; (ii) partial: r = -.28, p = 0.01; partial correlations for individual CpGs are also 
shown in Table 2). While this resulted in a considerable drop in effect size, the difference 
between the adjusted and non-adjusted correlation was not significant (Z = 1.06, p = .14). 
********************************** Table 2********************************* 
2. Wider analysis of methylomic variation across the DRD4 gene. Next, we 
examined whether any additional CpG sites annotated to this gene associated with 
engagement in physical fights at a nominal level. As can be seen in Table 3A, lower DNAm 
across 12 (i.e. 57%) out of the 21 probes annotated to DRD4 were nominally associated with 
higher engagement in physical fights (p < .05, bolded in table). Interestingly, these tended to 
show a high degree of variability, with most probes exceeding an SD > .10 (Table S2). To put 
this in context, only 9% of probes on the Illumina 450k array in this sample meet this 
threshold of variability. The results are visualized as a coMET plot (Martin, Yet, Tsai, & Bell, 
2015) in Figure 1. Based on ENCODE data extracted from the UCSC GenomeBrowser 
(GRCh37/hg19 assembly; Kent et al., 2002), we found that all DRD4 sites overlapped with at 
least one key regulatory element, suggesting that they are located in genomic regions that are 
likely to play a role in transcriptional activity (Table S2).  First, all sites overlapped with 
histone marks (only relevant cell lines examined, namely blood [GM12878] and umbilical 
vein endothelial [HUVEC] cells). Histone marks are chemical modifications that influence 
how tightly packaged the DNA is around a histone protein, regulating its accessibility. The 
strongest signal was found for H3K27me3 and H3K4me1, both of which are typically 
associated with active or potentially active enhancer regions (Zhu, et al., 2013).  Second, we 
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found that 90% (n = 19) of sites coincided with transcription factor binding sites (data 
generated from 91 cell-types) - DNA regions where one or more specific proteins responsible 
for regulating transcription bind to. This overlap was identified across multiple tissues 
spanning all three germ layers (i.e. endoderm, mesoderm and ectoderm), with the strongest 
signal linked to the EZH2 transcription factor, a functional enzymatic component of the 
Polycomb complex PRC2 that is involved in transcriptional repression and early development 
(Margueron & Reinberg, 2011). Finally, 71% (n = 15) of sites were located within DNAse I 
hypersensitive clusters (data generated from 125 cell-types), which tend to indicate an open 
chromatin state that facilitates transcription. As with the transcription factor binding sites, we 
found that overlap with DNAse I hypersensitivity clusters was observed across multiple 
tissues and germ layers, with the strongest signal identified for epithelial tissue.  
********************************** Figure 1********************************* 
********************************** Table 3********************************* 
3. Sensitivity analyses. We carried out a set of sensitivity analyses to test the 
robustness of associations between DRD4 methylation and our measure of physical 
aggression. First, we winsorized DNAm data to reduce the influence of potential outliers (> 3 
SD) using the DescTools package with default settings. The winsorizing method uses 
censoring rather than exclusion, which is preferable with small sample sizes (Sheskin, 2003). 
Second, we ran a surrogate variable analysis (sva package in R; Leek, Johnson, Parker, Jaffe, 
& Storey, 2012) to identify unwanted sources of variation in the genome-wide DNA 
methylation data. No significant surrogate variables were detected after correction for the 
covariates already included in the statistical model. To ensure that the observed associations 
were not biased by unknown confounders of smaller effect, we re-ran associations between 
the DRD4 sites and physical aggression additionally controlling for ten surrogate variables. 
Third, because buccal swabs can contain a mixture of different cells (mainly buccal epithelial 
cells and leukocytes) we tested the potential influence of cell-type heterogeneity on our 
findings, using two independent methods. The first derives a ‘predicted tissue’ based on DNA 
methylation patterns (Horvath, 2013), whereas the second uses two CpG sites to estimate the 
percentage of buccal epithelial cells for each individual (Eipel et al., 2016). Each of these 
estimates was then examined in relation to DRD4 methylation and physical aggression (see 
the Supplementary Methods for full details and results). Finally, given the skewed 
distribution of the variable measuring engagement in fights, we tested whether DRD4 sites 
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remain differentially methylated when collapsing the ordinal variable into a binary yes/no 
variable (i.e. 0 for ‘no fights’ [n = 88] vs 1 for ‘any fights’ [n = 31] over the past year).  
While slight variations in effect sizes were observed, results remained consistent 
across all of the above sensitivity analyses, indicating that the associations are unlikely to be 
unduly influenced by unwanted sources of variation or extreme scores in either DNAm or the 
engagement in fights variable (Spearman correlation of effect sizes: (i) original vs winsorised 
analysis: r = .92, p = 5.16E-09; (ii) original vs SVA-corrected analysis: r = .96, p = 1.94E-11; 
(iii) original vs cell-type restricted analysis: r = .91, p = 1.03E-08; and (iv) original vs binary 
fights analysis: r = .95, p = 6.71E-11; see Table S3 for full results). 
4. Saliva-blood concordance. Before proceeding to the replication step, we wanted to 
ensure that we could validly compare associations between DRD4 methylation and physical 
aggression across different peripheral tissues. This is because in our discovery sample, 
DNAm was drawn from buccal swabs, whereas in the replication sample it was extracted 
from blood (T cells). As we did not have access to multiple tissues in our discovery sample, 
we examined instead published data characterizing saliva-blood concordance for all Illumina 
450k probes, based on matched samples from 64 adults (Smith et al., 2015). Of note, the 
Smith et al. study examined saliva, not buccal swabs. However, these two DNA sources 
typically contain the same mixture of cell-types (i.e. buccal epithelial cells and leukocytes), 
although proportions of buccal epithelial cells tend to be higher in buccal swabs (Theda et al., 
2018). Furthermore, our sensitivity analyses for cell-type heterogeneity further supported the 
comparability of DRD4 DNAm patterns between buccal swabs and saliva (see 
Supplementary Methods). Based on the Smith et al resource, we found that, for 10 of the 12 
DRD4 sites associated with physical fights in our sample, DNAm levels in saliva significantly 
associated with DNAm levels in blood – including all sites contained in our DMR region (p 
range: 7.00E-09 – 1.24E-14; Table S2). This contrasted with 33% of the remaining sites that 
did not associate with physical fights.  More generally, across all DRD4 probes, the strength 
of association with physical fights in our sample correlated positively with the strength of 
saliva-blood concordance (r = 0.59, p = 0.01; Table S4).  
Step 2. Replication in peripheral T cells in an independent sample 
Given the above evidence for cross-tissue concordance, we proceeded to replicate our 
findings on DRD4 methylation in a different peripheral tissue (blood T cells) extracted from 
an independent sample of young adults following a low (LPA) vs chronic (CPA) trajectory of 
physical aggression from childhood to adolescence. Methylation values for one participant in 
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the LPA group were winsorized due to presence of outliers (>3 SD), even though findings 
were consistent when using the original values. Descriptive statistics are presented in Table 
3B, including means and standard deviations for each DRD4 site, percent methylation 
differences and associated effect sizes (Hedge’s g, given the small sample size). To facilitate 
comparability with the replication sample – which used a case-control design – we include the 
same descriptive information for our discovery sample, split into two groups based on the 
binary fights variable (i.e. ‘No fights’ vs ‘Any fights’).  
The direction of associations was consistent across both samples, with lower DNAm 
associating with higher physical aggression. On average (i.e. across all 21 probes annotated to 
DRD4), there was a 3.85% difference in DRD4 methylation between groups in our sample 
(range = 0.01-10.7%), compared to 3.06% in the replication sample (range = 0.20-8.14%). 
Effect sizes were typically modest in the discovery sample (mean g = -0.41) and large in the 
replication sample (mean g = -0.94). Table 3B also shows the results of the bootstrapped 
regression analyses in the replication sample. Overall, 8 of the 21 (38%) CpG sites in DRD4 
were significantly differentially methylated between groups, as evidenced by the bootstrapped 
CIs (bolded in table). Two of these were located in our genome-wide DMR (cg03909863, 
cg11335335), and three others were nominally significant in the discovery sample 
(cg06299284, cg06825142, cg23501406).  
As a more stringent test of replication, we created a poly-epigenetic score (ePGS) of 
DRD4 methylation, following a method commonly used in molecular genetic studies and 
recently extended to epigenetic data (Shah et al., 2015). Specifically, for each CpG site, we 
multiplied the methylation values from the replication sample by their respective standardized 
regression betas from the discovery sample (i.e. independent weights), and then summed these 
weighted DNAm values together into a single, cumulative risk score. This ePGS score was 
found to significantly associate with physical aggression in a bootstrapped regression model, 
showing lower methylation in the CPA vs LPA group (effect size g = -0.90, T = -1.73, SE = 
0.84, bootstrapped 95% CI = -3.44 – -0.15).   
Follow-up analysis: relevance to the brain 
1. Blood-CNS concordance in DRD4 methylation. The results from the replication 
analysis suggest that DNAm patterns in DRD4 may reliably associate with physical 
aggression across distinct peripheral tissues (buccal vs blood T cells). Yet, the extent to which 
these markers may reflect DNAm patterns in the brain is unclear. To address this, we 
investigated peripheral-CNS concordance in DRD4 methylation, using published Illumina 
18 
 
450k data from two independent sources. The first consisted of data from over 70 individuals 
for whom matched DNA samples were isolated from both premortem whole blood and 
postmortem CNS tissue across four brain regions (prefrontal cortex [PFC], entorhinal cortex 
[EC], superior temporal gyrus [STG] and cerebellum [CER]; Hannon et al., 2015; 
http://epigenetics.iop.kcl.ac.uk/bloodbrain). For descriptive purposes, we found that of the 12 
DRD4 sites nominally associated with physical fights in our sample, 10 (83%) showed 
significant blood-CNS correspondence with at least one brain region, including all five sites 
contained in our genome-wide DMR (for a table of associations with each brain region, see 
Table S2; for a visual example of associations with the top DRD4 probe cg07212818, see 
Figure S5). In contrast, blood-CNS correspondence with at least one region was observed for 
only 1 of the 9 (11%) DRD4 sites that were not associated with physical fights. In line with 
the findings on saliva-blood correspondence presented above, we found that, overall, the 
strength of associations with physical fights in our sample correlated significantly with the 
strength of blood-CNS associations in Hannon et al.’s sample. This was true across all four 
CNS tissues, with stronger associations observed for cortical (PFC: r = .69, p = 1.00E-03; 
SGT: r = .77, p = 5.40E-05; EC: r = .77, p = 4.90E-05) vs non-cortical tissue (cerebellum: r = 
.49, p = .02; Table S4). The difference in these correlations was significant when comparing 
the cerebellum to the SGT and EC (z-score = 2.67, p = .01), but not the PFC (z-score = 1.70, p 
= .09). Of note, one of the DRD4 sites that associated with physical aggression across both the 
discovery and replication sample (cg06299284) was reported in Hannon et al’s study to be 
one of only 5.39% of probes on the Illumina450k array where inter-individual variation 
predicted more of the variance in DNAm than tissue type.  
Blood-brain concordance was further confirmed using the second data source, 
consisting of paired samples of whole blood and three brain regions from 16 individuals 
(Broadmann area [BA] 7: parietal cortex; BA10: anterior prefrontal cortex; and BA20: 
inferior temporal cortex; Edgar et al., 2017; BECon online tool: 
https://redgar598.shinyapps.io/BECon/). Of note, four of the five probes contained in our 
DMR were reported by Edgar et al. to be in the top 10% of sites showing the strongest blood-
brain concordance in their sample (Table S2, which also includes information on all other 
DRD4 probes). Overall, DRD4 probes showed high variability and strong cross-tissue 
concordance in this sample. Regions that were most comparable across resources (e.g. 
Hannon’s prefrontal cortex and Edgar’s BA10) also showed the strongest convergence in 
findings, which adds validity to the results (Table S4). As with the other resources, the 
strength of associations with physical fights in our sample correlated with that of blood-brain 
19 
 
correspondence in Edgar et al.’s sample (r = .55, p = .01). A graphical representation of 
BECon results showing blood-brain variability and correspondence for DRD4 sites contained 
in our DMR is provided in Figure S5.  
 2. DRD4 expression in the brain. Given the above support for cross-tissue 
concordance in DRD4 methylation across saliva, blood and brain, we investigated expression 
levels of DRD4 in CNS vs peripheral tissues using the Genotype-Tissue Expression project 
portal (GTEx; http://www.gtexportal.org/home/; GTEx Consortium, 2015), which is based on 
data on 53 tissues from 544 donors. Expression levels across available brain regions as well as 
the three most relevant peripheral tissues to our study are graphically presented in Figure S5, 
including: (i) salivary gland, (ii) esophagus mucosa, which comprises of squamous epithelial 
cells that are part of the same cell-type family as buccal epithelial cells, and (iii) whole blood. 
Generally, DRD4 expression was low across all tissues, with the cerebellum showing the 
highest levels of expression in the brain. Other brain regions of relevance to physical 
aggression, including the frontal cortex, amygdala and hippocampus showed similar levels of 
expression to the two peripheral tissues closest to buccal cells (i.e. salivary gland and 
esophagus mucosa), whereas whole blood showed the lowest expression levels.  
 Step 3. Mendelian randomization analysis to test for causal pathways 
As a final step, we investigated whether peripheral DRD4 methylation exerts a causal effect 
on physical aggression using Mendelian randomization (MR) analysis. Of the 12 DRD4 sites 
nominally associated with physical aggression in our discovery sample, 6 (50%) were linked 
with at least one mQTL, suggesting that DNAm levels across these CpG sites are likely to be 
under considerable genetic control (Table S2). One of these mQTLs (cis SNP rs2740373) was 
eligible to be used as a genetic instrument in the MR analysis, as it was the only 
polymorphism which was investigated for an association with physical aggression, based on 
data from a recently published GWAS by the EAGLE Consortium (Pappa et al., 2015; n = 
18,832, p = 0.95). Of note, this mQTL was predictive of DNAm levels across three CpG sites, 
all of which were contained in the DMR (cg07212818, cg11335335, cg01616529; Table S2). 
Consequently, we ran three MR analyses with the same genetic instrument – one for each of 
these CpG sites. Across all CpG sites, MR results were non-significant, meaning that a causal 
effect of peripheral DNAm on engagement in physical fights was not supported, even though 
the direction of effects was consistent with the findings from our discovery and replication 
analyses (i.e. negative association between DNAm and physical aggression; for full results 
see Figure S6).  
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Discussion 
The overall aim of the present study was to characterize DNA methylation patterns associated 
with physical aggression, using a multi-sample, cross-tissue design. We highlight here three 
key findings. First, we conducted an epigenome-wide analysis of physical aggression – 
measured as engagement in physical fights – based on buccal cell DNA drawn from a sample 
of high-risk youth. We found that lower DNAm levels in one region spanning the DRD4 gene 
survived genome-wide correction, was associated with higher physical aggression over and 
above co-occurring symptomatology, and showed strong cross-tissue concordance with both 
blood and brain tissue. Second, we replicated these findings in an independent sample of 
young adults based on DNA from a different peripheral tissue (blood T cells). Specifically, 
we found that DRD4 methylation levels significantly differentiated between adults with a 
chronic-high vs low history of physical aggression in childhood and adolescence. Third, using 
published GWAS data from the EAGLE consortium, we ran a Mendelian randomization 
analysis to test for a causal effect of peripheral DRD4 methylation on aggression. Based on 
the only eligible genetic instrument, we did not find evidence to support causal effects. 
Overall, our findings point to peripheral DRD4 methylation as a potential biomarker of 
physical aggression, with no evidence yet supporting a causal association. 
The epigenetic signature of physical aggression in buccal cells 
Recent data suggests that DNAm in buccal cells may be a useful tool for the investigation of 
brain-based phenotypes, as they are derived from the same ectodermal layer as brain cells 
during development, and have been shown to correlate with CNS methylation more strongly 
than other commonly examined peripheral tissues, such as blood (Smith et al., 2015). So far, 
published epigenetic studies on physical aggression in humans have all made use of blood 
samples (Guillemin et al., 2014; Provencal, Suderman, Caramaschi, et al., 2013; Provençal et 
al., 2014; Dongsha Wang et al., 2012). Here, we performed the first genome-wide study 
characterizing DNAm patterns associated with physical aggression in buccal cells, using both 
probe- and region-level approaches. Of note, regional analyses are a useful complement to 
probe-level analyses, as they draw on the intercorrelated nature of DNAm data to alleviate 
multiple-testing burden, increase power to detect effects, and reduce the likelihood of false 
positives (Robinson et al., 2014).  
The key finding to emerge from our genome-wide analyses implicated epigenetic 
regulation of the Dopamine Receptor D4 (DRD4) gene – one of the most extensively studied 
candidate genes for aggression and related externalizing problems (Fernàndez‐Castillo & 
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Cormand, 2016). Specifically, we identified one region in the gene body of DRD4 that 
associated with engagement in physical fights after genome-wide correction (using two 
separate methods). More broadly, over half of all sites annotated to DRD4 showed at least 
nominal associations, whereby individuals who showed lower DNAm levels in these sites 
reported more frequent engagement in physical fights. These associations were robust to 
sensitivity tests and not unduly driven by extreme scores in either the DNAm data or the 
physical fights outcome variable. Furthermore, gene ontology analysis indicated significant 
enrichment for ‘dopamine receptor signaling’, supporting the probe- and region-level results. 
Together, these data converge on DRD4 methylation as the most robust epigenetic signal 
associated with physical aggression.  
Besides dopamine signaling, we identified enrichment of other biological processes 
relevant to aggression. One of these was ‘hormone metabolic processes’, with several high-
ranking DMPs annotated to thyroid hormone pathway genes (TRH, FDX1, TNX2, TXNRD2), 
consistent with prior evidence of thyroid hormone dysregulation in pathological aggression in 
humans (Evrensel, Unsalver & Ozsahin, 2016) and attack behavior in mice (Hrabovszky et 
al., 2005). Another set of enriched pathways related to inflammatory processes, including 
‘cytokine secretion’. This is in line with reported alterations in DNAm and expression levels 
of cytokine genes in individuals with a chronic history of childhood physical aggression 
(Provençal, Suderman, Caramaschi, et al., 2013; Provencal, Suderman, Vitaro, Szyf, & 
Tremblay, 2013), as well as in individuals diagnosed with Intermittent Explosive Disorder 
(Montalvo-Ortiz et al., 2017). We also identified enrichment for multiple CNS-related 
processes, such as ‘Axon guidance’. Interestingly, this same GO pathway was found to be 
highly enriched in the EWAS study on global aggression by van Dongen et al. (2015) as well 
as a recent bioinformatic analysis combining findings from six GWAS studies on aggression-
related phenotypes (Fernàndez‐Castillo & Cormand, 2016). Finally, we observed enrichment 
for regulation of ‘behavior’, which was again reported in the EWAS by van Dongen et al 
(2015) in a general population of twins, but also in the EWAS by Guillemin et al (2014) in 
adults following a chronic vs low trajectory of physical aggression in childhood. In summary, 
our findings point to an ‘epigenetic signature’ of physical aggression in buccal cells that is 
enriched for numerous biological processes, spanning neural, hormonal, immune and 
behavioral domains. 
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Findings support the involvement of DRD4 in aggressive behavior 
Dopamine is widely considered to be a key player in the neurobiology of aggressive behavior 
(Hagenbeek et al., 2016). Its uptake from the synaptic cleft is modulated by the dopamine 
receptor family, encoded by genes DRD1 through to DRD5. Of these, DRD4 has received the 
most attention for its potential role in aggression and related phenotypes (Pappa et al., 2015). 
Specifically, genetic variants of DRD4 that confer lower expression have been associated with 
higher aggression, delinquency and externalizing behavior in child and adult populations 
(Fernàndez‐Castillo & Cormand, 2016) as well as elevated risk for psychiatric diagnoses that 
are often accompanied by high aggression (e.g. CD, ADHD, ASPD, schizophrenia, substance 
use disorders; Ptacek, Kuzelova, & Stefano, 2011). Furthermore, DRD4 polymorphisms have 
been associated with temperamental and personality traits closely related to aggression, 
including sensation-seeking, risk-taking, impulsivity, anger and reward sensitivity (Munafò, 
Yalcin, Willis-Owen, & Flint, 2008). The genetic literature on DRD4, however, has been far 
from consistent, with several studies reporting null findings (see Pappa, Mileva-Seitz, 
Bakermans-Kranenburg, Tiemeier, & van IJzendoorn, 2015, for a review). It has been 
suggested that, in addition to methodological differences, these inconsistencies may reflect 
moderation by the environment, as the dopamine system is known to be responsive to 
environmental inputs across development (Vassos, Collier, & Fazel, 2014). 
The present study supports and extends previous findings of a link between DRD4 and 
aggression at multiple biological levels, from genetics to physiology. Specifically, it is the 
first to show that this link is also observable at the epigenetic level, with lower levels of 
DRD4 methylation found to associate with greater physically aggression. Interestingly, we 
found that several sites in the DMR were strongly associated with known genetic mQTLs 
(Gaunt et al., 2016) as well as showing small associations with environmental exposures in 
our sample, including neighborhood disadvantage and community violence exposure. While 
preliminary, these data are consistent with the hypothesis that DNAm patterns may reflect 
(and potentially mediate) the influence of genetic and environmental inputs on behavioral 
phenotypes (Uher, 2014). Although no study has specifically examined DRD4 methylation in 
the context of aggressive behavior, several studies have reported an association with related 
phenotypes – particularly risk of ADHD (e.g. Dadds, Schollar-Root, Lenroot, Moul, & 
Hawes, 2016; van Mil et al., 2014). The question therefore arises as to whether DNAm 
patterns in this gene may be specific to aggression, shared with – or even entirely confounded 
by – co-occurring symptomatology. To address this, we examined associations between the 
DRD4 DMR and common psychiatric and behavioral correlates of physical aggression. We 
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found that, besides physical aggression, DNAm levels in this region were most strongly 
correlated with self-reported drug use, followed by informant-rated levels of (low) prosocial 
behavior, callous-unemotional traits and externalizing – but not internalizing – psychiatric 
symptoms (esp. CD and ASPD). Overall, these findings are consistent with genetic studies 
implicating DRD4 in externalizing psychiatric symptoms and substance use (Ptacek et al., 
2011), as well as callous-unemotional and psychopathic traits (Yildirim & Derksen, 2015). In 
part, these shared associations may reflect the role of dopamine signaling in processes that are 
common to multiple externalizing problems, such as sensation-seeking, impulsivity and 
reward processing (Beauchaine & McNulty, 2013). Importantly, however, the association 
between DRD4 methylation and physical aggression was not entirely explained by shared 
variance with other functional domains, remaining significant even after adjusting for all co-
occurring symptomatology. Consequently, our findings suggest that while DRD4 methylation 
patterns may be shared across multiple forms of externalizing problems, they also show an 
independent association with physically aggressive behavior. In future, more work will be 
needed to identify what factors may be driving the shared vs unique associations observed 
between DRD4  methylation, physical aggression and co-occurring externalizing symptoms. 
Furthermore, an important avenue for future research will be to test whether specificity of 
associations can be improved if DRD4 methylation is combined with other known risk factors 
for physical aggression (e.g. across psychosocial, demographic and contextual domains), and 
conversely, whether the inclusion of DRD4 methylation in predictive models for physical 
aggression can result in greater predictive power and classification accuracy above the use of 
traditional risk factors alone.  
 
DRD4 methylation as a potential cross-tissue biomarker of physical aggression 
Having established a robust link between DRD4 methylation and physical aggression in 
buccal cells, we proceeded to test the degree to which these patterns may also be observed in 
other peripheral and central tissues. We found that for over 80% of DRD4 sites that were at 
least nominally associated with physical aggression in our sample (including all sites in the 
DMR region), DNAm levels in saliva significantly associated levels in blood. Our findings 
are consistent with previous reports of saliva-blood concordance in DRD4 methylation, 
including a recent study documenting comparable associations between DNAm levels and 
ADHD risk in these two peripheral tissues (Dadds et al., 2016).  
 Given evidence of strong concordance, our next aim was to replicate the DRD4-
aggression findings in blood, using the same sample upon which most of the epigenetic 
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studies of physical aggression to date have been based (Guillemin et al., 2014; Provençal, 
Suderman, Caramaschi, et al., 2013; Provençal et al., 2014; Dongsha Wang et al., 2012). Both 
samples were found to show consistency in the direction of associations with physical 
aggression (i.e. lower DNAm = higher physical aggression) as well as in the average DRD4 
methylation difference between groups (> 3%).  Furthermore, effect sizes were typically 
modest in the discovery sample (average g = -0.41) and large in the replication sample 
(average g = -0.94), which may reflect more precise phenotyping in the latter (i.e. discovery 
sample: self-reported item indexing engagement in fights in the past year; replication 
samples: trajectories of informant-rated physical aggression based on repeated longitudinal 
assessments). In the replication sample, we found that 38% of probes annotated to DRD4 
were differentially methylated between the CPA and LPA group (compared to 57% in the 
discovery sample), including two sites located in our genome-wide DMP. As a more stringent 
test of replication, we built a polyepigenetic score (ePGS), where DRD4 methylation levels 
from the replication sample were weighted by the (independent) effect sizes from the 
discovery sample, and found that this ePGS score was also differentially methylated between 
groups. 
The above findings suggest that DNAm patterns in DRD4 are comparable between 
buccal cells and blood, and reliably associate with physical aggression across these distinct 
peripheral tissues. Yet, based on this data alone, it is not possible to establish whether cross-
tissue concordance extends to the brain – likely the most relevant organ for the study of 
aggression. To test this, we examined peripheral-CNS correlations in DRD4 methylation, 
based on two independent data sources of matched premortem whole blood and postmortem 
brain tissue across (Hannon et al., 2015; Edgar et al., 2017). Similar to the saliva-blood 
findings, we found that the vast majority of DRD4 sites at least nominally associated with 
engagement in physical fights showed significant peripheral-CNS concordance across both 
resources, including all sites in our DMR. These findings are in line with data showing high 
concordance in DRD4 methylation patterns between blood and brain tissue in humans 
(Docherty et al., 2012) as well as in animals selectively bred for high vs low exploratory 
behavior (Verhulst et al., 2016). Interestingly, we found that physical aggression-related 
DRD4 sites showed stronger peripheral-CNS convergence in frontotemporal regions 
compared to the cerebellum.  However, it is important to note that we were not able to test 
whether DRD4 methylation levels in the brain also associate with physical aggression, which 
will require access to postmortem samples with recorded histories on this behavioral 
phenotype. 
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Overall, the strong cross-tissue concordance in DRD4 methylation observed in our 
study suggests that methylation status of this gene in easily accessible peripheral tissues, such 
as buccal cells and blood, may have utility as a valid proxy of methylation status in the brain. 
Furthermore, the robustness and reproducibility of our findings across independent samples 
and tissues points to DRD4  methylation as a potential biomarker for physical aggression, in 
line with the broad definition of a biomarker (Biomarkers Definitions Working Group, 2001). 
This, however, represents only the first step in a longer process of biomarker discovery and 
validation. In particular, it will be important to systematically evaluate the accuracy (i.e. 
sensitivity and specificity) of DRD4 methylation as a biomarker for physical aggression, in 
order to inform its potential translational applications.  
Probing causal pathways using Mendelian randomization  
Up to this point, our findings support DRD4 methylation as a potential cross-tissue biomarker 
for physical aggression, with strong concordance observed across buccal cells/saliva, blood 
and brain. Yet, this alone does not necessarily imply that DRD4 methylation plays a 
mechanistic role in physically aggressive behavior. In other words, a biomarker can be 
reliably associated with a phenotype of interest, without being causally related to it. 
Differentiating between causal and non-causal biomarkers is crucial for informing which 
translational application may be most appropriate (e.g. non-causal biomarker = use in 
detection, management and monitoring of symptoms; causal biomarker = potential target for 
prevention and treatment strategies). Based on functional studies on DRD4, DNAm levels in 
the gene body (i.e. where our DMR was located) have been found to positively associate with 
DRD4 gene expression (i.e. higher DNA methylation relating to higher gene expression; 
Cheng et al., 2014). Thus, the association between DNAm and physical aggression observed 
in the present study could be interpreted as indicating that: (i) lower gene body methylation is 
linked with lower DRD4 expression; which in turn (ii) relates to a lower density of DRD4 
receptors and decreased dopamine binding potential; thereby (iii) associating with higher 
physically aggressive behavior. Consistent with this, one study found that children with 
ADHD had lower concentrations of DRD4-mRNA in whole blood compared to a control 
group (Taurines et al., 2011). Furthermore, lower binding potential of D2-like dopamine 
receptors has been associated with a range of negative outcomes, including substance use and 
addiction (Martinez et al., 2007). 
Here, we tested for a causal effect of DRD4 methylation on physical aggression using 
Mendelian randomization analysis (Relton & Davey Smith, 2012). We found that only one of 
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the SNPs identified as mQTLs for DRD4 methylation in our sample had the necessary 
characteristics to be used as a genetic instrument in the MR analysis (i.e. the only one with 
available GWAS data on aggression; Pappa et al., 2015). Using this single SNP, we did not 
find evidence to support a causal association between peripheral DRD4 methylation and 
physical aggression, even though the direction of effects was consistent with our data (i.e. 
lower DNAm = higher aggression). If confirmed in future studies, these findings would 
suggest that peripheral DRD4 methylation patterns may have greater utility as a non-causal 
biomarker of physical aggression rather than an intervention (i.e. modifiable) target for 
strategies aiming to reduce aggressive behavior. However, it is important to note that, given 
the reliance on a single SNP, our findings do not preclude entirely the possibility of causal 
effects, and as such should not be interpreted as conclusive evidence for lack of causality. 
Furthermore, it is possible that, rather than exerting causal effects per se, peripheral DRD4 
methylation patterns reflect DNAm status in the brain, where causal effects on physical 
aggression are exerted. In order to evaluate this possibility, future MR studies should aim to 
select as genetic instruments only SNPs that reliably associate with DRD4 methylation 
patterns in both peripheral and brain tissue, which we were not able to ascertain in our study. 
Finally, the analysis had a number of additional limitations (see below), so that findings 
should be considered preliminary, until more-powered and comprehensive MR studies are 
conducted testing this association. 
Limitations and future directions  
The present findings should be interpreted in light of several limitations. First, our discovery 
and replication samples were relatively small. Although both samples were at high-risk of 
psychiatric symptomatology and showed variability in physically aggressive behavior – thus 
increasing power to detect effects – more work will be needed to replicate findings in larger 
populations. Of note, no sex differences in physical aggression were identified in our sample, 
which is consistent with prior research reporting less pronounced sex differences in 
aggression within high-risk youth (Connor, 2012). Second, our genome-wide analysis was 
based on one self-reported item indexing engagement in physical fights over the past year. 
From this item, it was not possible to ascertain whether participants had actually initiated the 
fight or not. However, the fact that this measure associated with informant-rated psychiatric 
and behavioral correlates of physical aggression in the expected direction, and that DRD4 
findings replicated in an independent sample of individuals with well-characterized histories 
of physical aggression adds confidence to the present results. 
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Third, although we identified significant convergence in aggression-related DRD4 
methylation patterns across peripheral and CNS tissues, associations with aggression were 
only verified in buccal cells and blood. Consequently, it will be important to replicate our 
findings in the brain, for example by using post-mortem samples (Bakulski et al., 2016) and 
imaging epigenetic strategies in live humans (Nikolova & Hariri, 2015; Walton et al., 2017). 
Bearing this in mind, the strong cross-tissue convergence in DRD4 methylation levels 
observed across tissues from different germ layers (ectoderm: buccal epithelial cells and 
brain; mesoderm: blood) is notable. Future studies should investigate whether this 
concordance may be driven by genetic effects – as supported by the large number of mQTLs 
associated with our DRD4 loci – and/or driven by stochastic and environmental effects 
occurring during early embryonic development, as in the case of metastable epialleles 
(Rakyan, Blewitt, Druker, Preis & Whitelaw, 2002). Indeed, when cross-checking our five 
DMR sites with a recently published list of potential metastable epialleles (Van Baak et al., 
2018), we found that none of the mQTL-associated sites were included the list, but conversely 
that one of the sites not associated with mQTLs (cg03909863) was listed as a candidate 
metastable epiallele. On a broader level, more work will be needed to characterize the cross-
tissue properties of mQTLs and expression patterns associated with our aggression-related 
DRD4 loci. 
Fourth, data on smoking status and medication use were not available in the present 
study.  In addition, our measures of substance use did not enable us to capture important 
characteristics, such as type, history and quantity of substance use, all of which may influence 
DNA methylation patterns. While we applied multiple strategies to minimize the possibility of 
residual confounding (e.g. SVA, independent replication, etc), future studies are needed to 
confirm our findings controlling for these potential confounders. It is noteworthy, however, 
that none of the DNAm sites identified in the present study overlapped with those found to be 
robustly affected by smoking in a recent systematic review (Gao et al., 2015). Fifth, we only 
focused on DRD4 methylation following our epigenome-wide analyses, given that this gene 
was identified using both probe- and region-level approaches, as well as converging with 
prior evidence from molecular genetic research implicating DRD4 in aggression. 
Nevertheless, our epigenome-wide analysis identified a number of additional DNA 
methylation sites of interest, which deserve further investigation in future.  
Finally, although MR findings did not support a causal association of peripheral DRD4 
methylation with physical aggression, it is important to note that analyses were based on the 
single, currently usable genetic instrument (rather than focusing on all SNPs implicated in our 
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analyses), and may have therefore been underpowered to detect what are likely to be small 
effects. Furthermore, GWAS data for the analysis was extracted from a study investigating 
global aggression (Pappa et al., 2015), as opposed to physical aggression per se, which 
denotes a particularly severe aggression phenotype (Tremblay, 2000). In future, studies 
should aim to use genetic instruments from larger samples and derived from multiple SNPs, 
which explain greater variance in DNAm. It will also be of interest to apply a two-way MR to 
examine the possibility of reverse causation – that is, whether greater physical aggression 
leads to lower DRD4 methylation.  This approach should be complemented with prospective, 
longitudinal studies featuring repeated measures of DRD4 methylation and physical 
aggression, in order to further disentangle the directionality of associations within a 
transactional framework. In order to systematically evaluate causality in the relationship 
between DRD4 methylation and physical aggression, it will also be necessary to triangulate 
findings from MR with those of other causal inference approaches ,  such as genetically-
informative twin studies and animal experimental models (Pingault, O’Reilly, Schoeler, 
Ploubidis, Rijsdijk & Dudbridge, 2018). Together, future work addressing these research gaps 
will mark an important step toward characterizing more precisely the potential translational 
utility of DRD4 methylation in the detection, prevention and management of physically 
aggressive behavior.  
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Table 1. Epigenome-wide analysis of engagement in physical fights: Top 30 DMPs 
CpG Probe Gene  Description Chr Position Genomic 
location 
Proximity 
to CpG 
Island 
Standardized 
Beta 
P-value FDR 
(q) 
cg21217577 TRH Thyrotropin-Releasing Hormone 3 129694683 Body Island -.49 2,07E-08 .01 
cg11107262 GAK Cyclin G Associated Kinase 4 871294 Body Island -.46 1,52E-07 .03 
cg27349081 RIC3 RIC3 Acetylcholine Receptor Chaperone 11 8190670 TSS200 Island .44 4,80E-07 .05 
cg27331554 CYFIP2 Cytoplasmic FMR1 Interacting Protein 2 5 156763290 Body - -.44 5,18E-07 .05 
cg05082738 LINC00301 Long Intergenic Non-Protein Coding RNA 301  11 60414918 Body Island -.43 1,03E-06 .08 
cg15916166 FAIM Fas Apoptotic Inhibitory Molecule 3 138327519 TSS200 Island .42 1,79E-06 .11 
cg07212818 DRD4 Dopamine Receptor D4 11 638076 Body Island -.42 2,16E-06 .11 
cg05717871 DRD4 Dopamine Receptor D4 11 638507 Body Island -.42 2,23E-06 .11 
cg03909863 DRD4 Dopamine Receptor D4 11 638404 Body Island -.42 2,29E-06 .11 
cg08455772 FLJ12825 Uncharacterized LOC440101 12 54452069 Body North Shelf -.41 3,92E-06 .16 
cg22175303 FAIM Fas Apoptotic Inhibitory Molecule 3 138327450 TSS200 North Shore .40 5,20E-06 .19 
cg11335335 DRD4 Dopamine Receptor D4 11 637885 Body Island -.40 5,63E-06 .19 
cg13694680 FIBIN Fin Bud Initiation Factor Homolog 11 27016671 1stExon - .40 7,44E-06 .23 
cg05930207 GJD3 Gap Junction Protein, Delta 3, 31.9kDa 17 38518520 1stExon North Shore -.40 8,23E-06 .23 
cg01616529 DRD4 Dopamine Receptor D4 11 638424 Body Island -.40 8,43E-06 .23 
cg11481687 - - 14 105499998 - Island .39 1,05E-05 .27 
cg03205258 TXNRD2;COMT Thioredoxin Reductase 2; Catechol-O-Methyltransferase 22 19929274 1stExon Island .39 1,22E-05 .29 
cg02445292 FCGBP Fc Fragment Of IgG Binding Protein 19 40417583 Body North Shelf .39 1,25E-05 .29 
cg04580929 PDE4D Phosphodiesterase 4D, CAMP-Specific 5 59711378 5'UTR - -.39 1,39E-05 .30 
cg00996790 - - 8 1432751 - South Shore -.38 1,63E-05 .31 
cg10105971 SGK1 Serum/Glucocorticoid Regulated Kinase 1 6 134638867 1stExon Island -.38 1,68E-05 .31 
cg11153328 TXN2 Thioredoxin 2 22 36877737 TSS200 - .38 1,69E-05 .31 
cg10096566 - - 14 95231817 - North Shelf -.38 1,74E-05 .31 
cg14234104 ANO1 Anoctamin 1, Calcium Activated Chloride Channel 11 69931467 TSS200 North Shelf .38 1,92E-05 .33 
cg13822329 - - 10 130855111 - - .38 2,10E-05 .35 
cg26312965 SDF4 Stromal Cell Derived Factor 4 1 1152547 3'UTR Island -.38 2,36E-05 .37 
cg10734526 GPM6B Glycoprotein M6B X 13956917 TSS200 Island .38 2,40E-05 .37 
cg01836910 CDK18 Cyclin-Dependent Kinase 18 1 205496136 Body North Shore -.38 2,47E-05 .37 
cg06674932 FDX1 Ferredoxin 1 11 110299342 TSS1500 North Shore .38 2,62E-05 .37 
cg23720732 SLC12A5 Solute Carrier Family 12, Member 5                  
(Potassium/Chloride Transporter) 
20 44650380 5'UTR North Shore .37 3,00E-05 .41 
Table 2. Associations between methylomic variation in the DRD4 DMR and known correlates of physical aggression 
   
N of fights in 
the past year
a
 
  
Environmental risks
b
 
  
Individual functioning 
                
Internalizing symptoms
c
 
 
Externalizing symptoms
c
 
 
Socio-emotional function
c
 
 
Substance use
b
 
  
Bivariate 
r 
Partial 
r  
Childhood 
maltreatment 
CVE IMD 
 
GAD MDD 
Internalizing 
total  
ADHD ODD CD ASPD 
Externalizing 
total  
Prosocial 
behavior 
CU            traits 
 
Alcohol 
use 
Drug             
use 
N of fights in the past 
year 
- - 
 
.26** .39*** .26** 
 
.23* .21* .23* 
 
.41*** .31*** .44*** .52*** .45*** 
 
-.21* .29** 
 
.20* .49*** 
DRD4 Methylation 
(DMR)                       
    Individual CpGs 
                      
         cg07212818 -.36*** -.26** 
 
-.17 -.21* -.11 
 
-.15 -.19 -.17 
 
-.24* -.13 -.22* -.30*** -.24* 
 
.30** -.34*** 
 
.17 -.37*** 
         cg05717871 -.37*** -.23** 
 
-.15 -.20* -.23* 
 
-.12 -.19 -.15 
 
-.21* -.15 -.25* -.26* -.23* 
 
.33*** -.35*** 
 
.03 -.46*** 
         cg03909863 -.32*** -.16 
 
-.16 -.15 -.23* 
 
-0,1 -.20 -.14 
 
-.15 -.07 -.20 -.25* -.15 
 
.23* -.30** 
 
.01 -.43*** 
         cg11335335 -.38*** -.30*** 
 
-.11 -.27** -.20* 
 
-.01 -.08 -.05 
 
-.12 -.05 -.23* -.20* -.13 
 
.29** -.25* 
 
-.07 -.33*** 
         cg01616529 -.34*** -.22** 
 
-.10 -.12 -.15 
 
-.04 -.12 -.08 
 
-.18 -.09 -.32** -.33*** -.20 
 
.29** -.35*** 
 
.03 -.41*** 
   DMR Principal 
component 
-.39*** -.28** 
 
-.16 -.13 -.21* 
 
-.12 -.19 -.15 
 
-.23* -.14 -.29** -.33*** -.24* 
 
.35*** -.35*** 
 
.07 -.45*** 
 
Spearman correlations; * p < .05, ** p < .01, ***p <.001.                                          
Abbreviations. CVE, community violence exposure; IMD, index of multiple deprivation; GAD, generalized anxiety disorder; MDD, major depressive disorder; ADHD, attention-deficit hyperactivity disorder; ODD,  
oppositional defiant disorder; CD conduct disorder; ASPD, antisocial personality disorder; CU, callous-unemotional. 
a
 Correlations between DRD4 methylation and engagement in physical fights, showing bivariate (unadjusted) spearman rho coefficients on the left, and partial  rho coefficients on the right, adjusting for all domains  
of individual functioning. 
 
      
b
 Self-report; n = 119                                             
c
 External-report, n = 95                                             
 Table 3. Methylomic variation across the DRD4 gene and replication in an independent sample 
 
 
A. Association between DRD4 probes and                                       
engagement in physical fights 
B. Replication analysis 
CpG Genomic 
location 
Proximity 
to CpG 
island 
Position Standardized 
B 
 
 
 
P-value   Discovery sample, split into two groups for comparability                         
(buccal epithelial cells)                                 
Replication sample                                                                                                                                                                                                                                
(peripheral T cells; pooled DNA from 38 individuals) 
    Overall sample            
(n = 119) 
No fights group               
(n = 88) 
  Fights group            
(n = 31) 
% Diff Effect 
size g 
  Overall sample  
(n = 12) 
  LPA group                            
(n = 6) 
CPA group                            
(n = 6) 
%
Diff 
Effect 
size g 
  Bootrapped estimates 
 
  M Sd M Sd   M Sd       M Sd   M Sd   M Sd       beta SE LCI UCI 
cg07212818 Body Island 638076 -0,42 2,16E-06   0,41 0,08 0,43 0,07   0,37 0,09 -6,3% -0,83   0,59 0,04   0,60 0,03   0,58 0,06 -2,0% -0,40   -0,02 0,03 -0,08 0,03 
cg05717871 Body Island 638507 -0,42 2,23E-06   0,59 0,13 0,62 0,12   0,52 0,13 -10,7% -0,85   0,79 0,06   0,82 0,02   0,77 0,08 -4,6% -0,72   -0,05 0,04 -0,12 0,03 
cg03909863 Body Island 638404 -0,42 2,29E-06   0,87 0,11 0,89 0,08   0,80 0,15 -9,4% -0,90   0,97 0,02   0,98 0,00   0,96 0,02 -1,5% -1,04   -0,02 0,01 -0,04 -0,001 
cg11335335 Body Island 637885 -0,40 5,63E-06   0,44 0,12 0,47 0,11   0,37 0,12 -10,0% -0,86   0,35 0,07   0,39 0,04   0,31 0,07 -7,9% -1,23   -0,08 0,03 -0,18 -0,04 
cg01616529 Body Island 638424 -0,40 8,43E-06   0,52 0,13 0,54 0,12   0,45 0,15 -9,4% -0,75   0,74 0,06   0,77 0,02   0,72 0,08 -4,6% -0,71   -0,05 0,03 -0,11 0,01 
cg09386376 Body Island 638939 -0,32 3,57E-04   0,65 0,11 0,67 0,10   0,59 0,12 -7,3% -0,68   0,75 0,04   0,76 0,02   0,74 0,05 -2,2% -0,52   -0,02 0,03 -0,07 0,03 
cg14433983 TSS1500 Island 636460 -0,30 7,72E-04   0,71 0,08 0,72 0,08   0,68 0,08 -4,7% -0,56   0,88 0,02   0,89 0,02   0,87 0,03 -2,3% -0,98   -0,02 0,01 -0,06 0,00 
cg06299284 TSS1500 Island 636659 -0,26 3,70E-03   0,39 0,12 0,41 0,11   0,34 0,11 -6,2% -0,54   0,64 0,06   0,68 0,04   0,59 0,05 -8,1% -1,68   -0,09 0,03 -0,13 -0,01 
cg03855291 Body Island 639423 -0,26 4,13E-03   0,48 0,12 0,49 0,11   0,43 0,14 -5,7% -0,48   0,54 0,03   0,55 0,03   0,53 0,02 -2,3% -0,79   -0,02 -0,02 -0,06 0,02 
cg06825142 TSS200 Island 637170 -0,23 0,01   0,09 0,02 0,09 0,02   0,08 0,01 -1,1% -0,60   0,05 0,01   0,05 0,01   0,04 0,01 -1,2% -1,45   -0,01 0,00 -0,02 -0,003 
cg23501406 TSS1500 Island 637035 -0,20 0,03   0,06 0,02 0,06 0,02   0,06 0,01 -0,6% -0,39   0,11 0,04   0,13 0,03   0,09 0,04 -4,1% -1,20   -0,04 0,02 -0,08 -0,01 
cg16029939 Body Island 640328 -0,18 0,05   0,40 0,12 0,41 0,12   0,36 0,11 -5,7% -0,49   0,10 0,04   0,12 0,04   0,09 0,01 -3,4% -0,97   -0,04 0,03 -0,07 0,02 
cg12928379 TSS200 Island 637175 0,14 0,13   0,07 0,01 0,06 0,01   0,07 0,01 0,4% 0,36   0,04 0,01   0,05 0,01   0,04 0,01 -1,1% -1,35   -0,01 0,01 -0,02 -0,002 
cg00556112 TSS200 Island 637173 -0,14 0,14   0,12 0,02 0,12 0,02   0,11 0,02 -1,0% -0,48   0,06 0,01   0,06 0,01   0,06 0,01 -0,5% -0,41   -0,01 0,01 -0,02 0,01 
cg02762115 Body Island 640446 0,11 0,26   0,55 0,11 0,55 0,11   0,56 0,13 0,3% 0,03   0,25 0,05   0,27 0,05   0,23 0,04 -4,6% -0,95   -0,05 0,03 -0,10 0,01 
cg08726248 TSS1500 Island 637032 -0,10 0,27   0,06 0,01 0,06 0,01   0,06 0,01 -0,1% -0,10   0,08 0,03   0,09 0,03   0,07 0,03 -1,8% -0,58   -0,02 0,02 -0,05 0,01 
cg20931042 TSS200 Island 637162 -0,09 0,34   0,08 0,01 0,08 0,02   0,08 0,01 -0,1% -0,07   0,06 0,02   0,07 0,01   0,05 0,01 -2,1% -1,71   -0,02 0,01 -0,03 -0,01 
cg09607276 1stExon Island 637491 -0,08 0,37   0,07 0,03 0,07 0,03   0,07 0,02 -0,3% -0,12   0,08 0,01   0,08 0,01   0,08 0,01 -0,8% -0,72   -0,01 0,01 -0,02 0,00 
cg23231692 TSS1500 N_Shore 636167 0,07 0,46   0,84 0,03 0,84 0,03   0,84 0,03 0,0% 0,00   0,97 0,01   0,97 0,01   0,96 0,01 -0,2% -0,28   0,00 0,00 -0,02 0,01 
cg15861585 TSS1500 Island 637038 -0,03 0,78   0,07 0,02 0,07 0,02   0,07 0,02 -0,2% -0,10   0,13 0,04   0,16 0,04   0,10 0,03 -5,4% -1,42   -0,06 0,02 -0,10 -0,02 
cg20411756 3'UTR Island 640606 0,00 0,98   0,72 0,13 0,73 0,12   0,70 0,16 -2,6% -0,20   0,15 0,05   0,17 0,05   0,13 0,04 -3,3% -0,68   -0,03 0,03 -0,10 0,00 
                                                                  
Figure 1. coMET plot of DRD4 methylation 
 
 
 
N.b. from top to bottom: (i) the genomic location of all CpG sites annotated to DRD4; (ii) 
their strength of association with physical fights; (iii) their overlap with key regulatory 
elements; and (iv) their pattern of intercorrelations. 
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Supplementary Methods 
Optimized gene ontology method 
A logistic regression approach was used to test if genes in the test list predicted pathway 
membership while controlling for the number probes annotated to each gene. Pathways were 
downloaded from the Gene Ontology website and all genes annotated to parent terms were 
also included. Illumina UCSC gene annotation was used to create a test gene list from probes 
that were associated with engagement in physical fights (p< 0.001). All genes with at least 
one methylation probe annotated and annotated to at least one GO pathway were considered. 
Pathways were filtered to those with between 10 and 2000 genes in. After applying this 
method to all pathways, significant pathways (p < 0.05) were taken and grouped where 
overlapping genes explained the signal. This was achieved by taking the most significant 
pathway, and retesting all remaining significant pathways while controlling additionally for 
the best term. If genes in the test list no longer predicted the pathway, the term was said to be 
explained by the most significant pathway, and hence these pathways were grouped together. 
This algorithm was repeated, taking the next most significant term, until all pathways had 
been considered as the most significant or found to be explained by a more significant term. 
GO terms were interpreted exclusively if they if they contained at least 2 genes and passed 
FDR-correction (q < 0.05), based on the final list of independent (non-redundant) terms.  
  
Mendelian Randomization (MR) analysis 
To run the MR analysis, we first selected genetic instruments (i.e. SNPs) for the identified 
DNAm markers using the mQTLdb database (http://www.mqtldb.org). The mQTLdb 
database contains the results of a study comprising 1000 mother-child pairs drawn from the 
Accessible Resource for Integrated Epigenomics Studies (ARIES; Relton et al., 2015), 
characterizing genome-wide significant SNP effects on DNAm levels for all Illumina 450k 
probes across five different life stages - birth, childhood, adolescence, pregnancy and middle 
age (Gaunt et al., 2016). SNP effects were examined both in cis (i.e. SNP within ±1000 base 
pairs of the DNAm site) and in trans (i.e. ±1 million base pairs). Here, we searched for the 
most representative, independent SNPs associated with our identified DNAm markers using 
the ‘Genome-wide Complex Trait Analysis’ (GCTA)  setting, which was used to account for 
linkage disequilibium. To increase specificity with respect to the developmental period under 
investigation (i.e. adolescence), we selected the adolescence-specific mQTL weights and 
associated standard errors for use in the MR analysis, which were available under the ‘Plink’ 
setting. Once the appropriate SNPs were identified from the mQTLdb search, we proceeded to 
extract summary statistics about their association with physically aggressive behavior, based 
on recently published GWAS data from the EAGLE consortium encompassing 18,988 
children and adolescents across nine cohorts (Pappa et al., 2015). Finally, the results from the 
mQTLdb search (i.e. SNP -> DNAm) and the GWAS data (i.e. SNP ->  physical aggression) 
were included in the MR analysis, which was carried out using the TwoSampleMR package in 
R, available as part of the MR-Base platform (www.mrbase.org; Hemani et al., 2016).  
 
Evaluating the influence of cell-type heterogeneity on our findings 
While the use of buccal swabs typically results in greater cell-type homogeneity than other 
oral sample alternatives (e.g. saliva collection via passive drool; Theda et al 2018),  these 
samples can still contain a mixture of different cell-types, namely buccal epithelial cells and 
leukocytes. To date, few methods have been developed for estimating cell-type heterogeneity 
in buccal swab samples, and these lack  extensive validation (Langie et al., 2017). Bearing 
this in mind, we used two available methods that await full validation to examine the 
influence of cell-type heterogeneity on our findings:  
First, we used the Horvath online age calculator (Horvath, 2013) to derive ‘predicted tissue’. 
Although the goal of this calculator is to estimate epigenetic ‘age’ based on DNA methylation 
data, it also provides additional output, including an estimate of predicted tissue (i.e. most 
likely tissue that each sample is derived from). The results from this analysis indicated that 94 
out of the 119 participants (79%) were correctly classified as ‘buccal’, and the remaining 25 
participants were classified as ‘saliva’. No other tissue was predicted. As a sensitivity 
analysis, we reran regression models between the DRD4 sites and physical aggression only in 
the subsample of participants with a buccal predicted tissue. The findings were highly 
consistent, with all sites that were at least nominally associated with physical aggression in 
the full sample (including probes in our DMR) remaining significant in the subsample 
(concordance between original and buccal-restricted analysis: r = .91, p = 1.03E-08; results 
showin in Table S3). Of note, associations also remained significant in the subsample 
predicted as saliva, which supports our use of the data published by Smith et al (2014), to 
examine cross-tissue concordance between saliva and blood.  
Second, we used the “Buccal-Cell-Signature” formula developed by Eipel et al (2016) to 
estimate the percentage of buccal epithelial cells, based on DNA methylation values from two 
CpG sites: Buccal-Cell-Signature formula = (99.8(β-value of cg07380416) + 1.92) / 2 + 
(−98.12 (β-value of cg20837735) + 88.54) / 2.The predicted fraction of buccal cells derived 
from our sample ranged between 22-84%, similar to the range reported by Eipel et al in their 
study (24-91%). We found that this variable did not correlate with either DRD4 methylation 
levels (e.g. correlation with the DMR PCA: r = -0.15; p = 0.10) or with engagement in 
physical fights (r = 0.03; p = 0.75), making buccal cell fraction an unlikely confounder in the 
association between DRD4 and aggression. This was confirmed using a Spearman partial 
correlation, which showed that this association was virtually unchanged after controlling for 
buccal cell fraction (bivariate:  rho = -0.39, p = 1.06E-05; partial: rho = -0.40, p = 9.00E-06).  
Given that both methods await further validation, these findings should be interpreted with 
caution. Reassuringly, however, the two methods showed good convergence with one another 
(r = 0.73, p = 7.14E-21). Together, the above findings suggest that cell-type heterogeneity is 
unlikely to have affected our results.  
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Table S1. Gene ontology (GO) analysis results 
GO Pathway ngenes in 
input list  
 Total nin 
pathway 
% p-value GO ID Genes 
Biological Processes             
negative regulation of receptor-
mediated endocytosis 
3 10 30% 2.94E-10 GO:0048261 RAC1;PICALM;ARF6 
positive regulation of 
phosphatidylinositol 3-kinase 
activity  
5 25 20% 4.66E-10 GO:0043552 EPHA8;PDGFRB;RAC1;PTK
2;VAV2 
positive regulation of protein 
kinase B signaling  
9 71 13% 1.18E-09 GO:0051897 SEMA5A;EGFR;PTK2;TCF7
L2;GATA3;NOX4;IGF1R;C1
QTNF1;CCL3 
negative regulation of axon 
extension involved in                    
axon guidance 
3 10 30% 1.66E-09 GO:0048843 SEMA3F;SEMA5A;SLIT1 
positive regulation of 
keratinocyte differentiation 
3 12 25% 1.05E-08 GO:0045618 NOTCH1;PRKCH;NCOA3 
regulation of hormone 
metabolic process 
5 27 19% 1.13E-08 GO:0032350 POR;TCF7L2;GATA3;IGF1R
;CACNA1A 
establishment of nucleus 
localization 
3 11 27% 1.23E-08 GO:0040023 SYNE1;PTK2;SLIT1 
coronary vasculature 
development 
3 13 23% 1.76E-07 GO:0060976 PDGFRB;NOTCH1;TBX1 
cochlea morphogenesis 4 22 18% 2.11E-07 GO:0090103 GLI2;RAC1;PAX2;TBX1 
regulation of interleukin-5 
production 
3 13 23% 7.50E-07 GO:0032674 PRKCZ;PDE4D;GATA3 
tongue development 4 19 21% 8.72E-07 GO:0043586 PRDM16;WNT10A;EGFR;TB
X1 
negative regulation of 
behavior 
5 37 14% 8.86E-07 GO:0048521 SEMA3F;TRH;SEMA5A;NOT
CH1;SLIT1 
dopamine receptor signaling 
pathway 
4 24 17% 1.51E-06 GO:0007212 CALY;DRD4;GNAO1;GNAL 
negative regulation of 
axonogenesis 
6 46 13% 2.21E-06 GO:0050771 SEMA3F;SEMA5A;SYNGAP1
;PTK2;SLIT1;ARHGEF1 
regulation of glial cell 
proliferation 
3 15 20% 3.42E-06 GO:0060251 SKI;NOTCH1;PRKCH 
circadian rhythm 8 89 9% 3.47E-06 GO:0007623 BTBD9;EGFR;ADK;DRD4;R
BM4B;TPH2;CRY1;RORA 
pharyngeal system development 3 16 19% 4.21E-06 GO:0060037 PLXNA2;GATA3;TBX1 
circadian regulation of gene 
expression 
3 18 17% 6.20E-06 GO:0032922 ADK;RBM4B;CRY1 
cytokine secretion 4 29 14% 6.73E-06 GO:0050663 AIM2;TRIM27;NOTCH1;GA
TA3 
neuron projection 
morphogenesis 
30 514 6% 7.43E-06 GO:0048812 PLXNB3;NTRK1;EPHA8;PL
XNA2;GLI2;CREB1;SEMA3F
;SEMA5A;EGFR;RAC1;FEZ
F1;BAI1;ANK1;PTK2;NOTC
H1;VAV2;TLN1;COL5A1;AN
K3;GATA3;SLIT1;PAX2;PIC
ALM;WEE1;ATP8A2;IGF1R;
PTPRM;MYL12B;CACNA1A;
BRSK1 
response to ethanol 9 109 8% 8.16E-06 GO:0045471 NTRK1;SDF4;TRH;GSN;MG
MT;GATA3;HTR3A;DRD4;A
ACS 
regulation of protein targeting 
to membrane 
3 18 17% 8.28E-06 GO:0090313 FIS1;ANK3;KCNE1 
semaphorin-plexin signaling 
pathway 
3 17 18% 1.17E-05 GO:0071526 PLXNA2;SEMA3F;RAC1 
establishment of cell polarity 7 65 11% 2.19E-05 GO:0030010 PRKCZ;PTK2;WEE1;ARF6;I
GF1R;NDE1;BRSK1 
regulation of cellular 
component organization 
58 1468 4% 3.10E-05 GO:0051128 PLXNB3;GPM6B;NTRK1;PR
KCZ;FMN2;AIM2;SHOX2;U
BE2E1;SEMA3F;RUFY1;NE
UROG1;SEMA5A;PDGFRB;
SYNGAP1;BTBD9;SGK1;FO
XK1;MAD1L1;RAC1;FIS1;A
NK1;PTK2;DLC1;PPP3CC;T
ERF1;NOTCH1;ARPC5L;CR
EB3;GSN;VCP;COL5A1;AN
K3;MTG1;TCF7L2;GATA3;C
ALY;SLIT1;NRG3;PAX2;PIC
ALM;NOX4;PRKCH;ARF6;S
NW1;ISLR2;BUB1B;TBCD;C
DC42EP4;ACCN1;SEZ6;PS
MC5;CCL3;MYL12B;CACNA
1A;ARHGEF1;TIAM1;C21orf
2;KCNE1 
digestive tract morphogenesis 6 54 11% 3.33E-05 GO:0048546 GLI2;SHOX2;FOXP4;EGFR;
NOTCH1;TCF7L2 
white fat cell differentiation 3 12 25% 3.60E-05 GO:0050872 PRDM16;NCOR2;AACS 
negative regulation of ion 
transport 
6 67 9% 6.12E-05 GO:0043271 GPM6B;PPOX;TRH;TRIM27
;GNAO1;ERG 
regulation of actin filament-
based process 
15 248 6% 8.19E-05 GO:0032970 GPM6B;FMN2;PDE4D;SEM
A5A;PDGFRB;RAC1;DLC1;
ARPC5L;GSN;NOX4;FRMD
6;ARF6;DSC3;KCNE1;ERG 
artery morphogenesis 5 48 10% 9.07E-05 GO:0048844 PDGFRB;CHD7;NOTCH1;T
BX2;TBX1 
vesicle coating 4 39 10% 1.14E-04 GO:0006901 COPA;SEC31A;CALY;PICAL
M 
response to drug 20 395 5% 1.17E-04 GO:0042493 NTRK1;PPOX;AIM2;ABCG5
;HDAC4;CREB1;EGFR;POR
;TERF1;MGMT;GATA3;AAC
S;CYP1A2;GNAO1;RPH3AL;
PTPRM;SLC12A5;ERG;CO
MT;TXN2 
regulation of system process 28 584 5% 1.24E-04 GO:0044057 APLN;GPM6B;NTRK1;PRK
CZ;HSPB7;SKI;PPOX;ABCG
5;HDAC4;KNG1;PDE4D;SY
NGAP1;BTBD9;SGK1;EGFR
;MTG1;TCF7L2;ADK;DRD4
;SHANK2;GNAO1;ACCN1;C
CL3;PTPRM;DSC3;CACNA1
A;KCNE1;ERG 
regulation of protein 
localization 
21 450 5% 1.25E-04 GO:0032880 GPM6B;PRKCZ;AIM2;SEM
A5A;TRIM27;EGFR;SLC26A
4;FIS1;DLC1;PPP3CC;CRE
B3;ANK3;TCF7L2;GATA3;P
ICALM;DRD4;ARF6;RPH3A
L;CCL3;KCNE1;RANGAP1 
positive regulation of DNA 
replication 
5 53 9% 1.36E-04 GO:0045740 GLI2;EGFR;RAC1;IGF1R;M
AP2K4 
regulation of cellular 
component movement 
26 554 5% 1.46E-04 GO:0051270 PLXNB3;PLXNA2;SEMA3F;
PDE4D;SEMA5A;PDGFRB;
SGK1;BMPER;EGFR;RAC1;
CDK6;PTK2;DLC1;NOTCH1
;CREB3;GATA3;SLIT1;NOX
4;ROBO4;ONECUT1;IGF1R
;CCL3;PTPRM;DSC3;KCNE
1;ERG 
glucosamine-containing 
compound metabolic process 
3 25 12% 1.47E-04 GO:1901071 NAGK;PGM3;GNE 
nervous system process 58 1616 4% 1.67E-04 GO:0050877 TBL1X;CLCN5;APLN;NTRK
1;CNIH3;PRKCZ;PPOX;CO
PA;ABCG5;HDAC4;KCNJ3;
CREB1;VIPR1;CPA3;KNG1;
PDE4D;COL11A2;SYNGAP1
;BTBD9;SGK1;EGFR;SLC26
A4;PTK2;CHD7;DFNB31;TL
N1;ANK3;GATA3;SLIT1;PA
X2;HTR3A;DRD4;SHANK2;
RIC3;TNNI2;KCNA6;PRPH;
ATP8A2;SLC24A4;APBA2;T
RPM1;A2BP1;GNAO1;CRY
M;ACCN1;SEZ6;MC2R;GNA
L;MYL12B;CACNA1A;AP3D
1;BRSK1;SLC12A5;KCNE1;
ERG;COMT;TBX1;PI4KA 
sensory perception of 
mechanical stimulus 
10 138 7% 2.07E-04 GO:0050954 TBL1X;NTRK1;COL11A2;SL
C26A4;CHD7;DFNB31;CRY
M;ACCN1;KCNE1;TBX1 
regulation of heart 
morphogenesis 
3 23 13% 2.66E-04 GO:2000826 NOTCH1;TBX2;TBX1 
ventricular cardiac muscle cell 
action potential 
3 21 14% 2.68E-04 GO:0086005 DSC3;KCNE1;ERG 
response to organic cyclic 
compound 
27 647 4% 2.78E-04 GO:0014070 NTRK1;NFIA;GSTM3;LIN28
;GLI2;TRH;PDE4D;PDGFR
B;EGFR;GSN;MGMT;GATA
3;HTR3A;DRD4;NOX4;NCO
R2;AACS;TPH2;IGF1R;CYP
1A2;GNAO1;CCL3;GNAL;K
CNE1;HLCS;COMT;TXN2 
inositol lipid-mediated 
signaling 
10 162 6% 3.52E-04 GO:0048017 NTRK1;CREB1;PDGFRB;E
GFR;GSN;GATA3;IGF1R;B
UB1B;TNRC6C;PI4KA 
vesicle-mediated transport 35 903 4% 3.61E-04 GO:0016192 CLCN5;RER1;FMN2;SDF4;
COPA;TUBA4A;KNG1;SEC3
1A;RUFY1;CYFIP2;EXOC2;
KIAA1244;RAC1;ANK1;PTK
2;ATP6V1H;VAV2;TLN1;GS
N;VCP;ANK3;CALY;LDLRA
D3;PICALM;RIN1;CD63;AR
F6;COG4;RPH3AL;CCL3;C
ACNA1A;AP3D1;ICAM5;TR
APPC10;SNAP29 
positive regulation of ion 
transport 
9 143 6% 3.81E-04 GO:0043270 PPOX;TRH;PDGFRB;CREB
3;ANK3;DRD4;CCL3;KCNE
1;ERG 
positive regulation of 
membrane potential 
3 21 14% 3.82E-04 GO:0045838 PRKCZ;ANK3;DRD4 
eating behavior 3 26 12% 3.88E-04 GO:0042755 PPOX;TRH;ATP8A2 
mitotic spindle assembly 
checkpoint 
4 33 12% 3.98E-04 GO:0007094 UBE2E1;MAD1L1;TERF1;B
UB1B 
negative regulation of BMP 
signaling pathway 
4 37 11% 5.18E-04 GO:0030514 SKI;BMPER;NOTCH1;TCF7
L2 
gland development 16 285 6% 5.48E-04 GO:0048732 APLN;GLI2;WNT10A;CREB
1;PDGFRB;EGFR;NOTCH1;
MGMT;TCF7L2;GATA3;NR
G3;NCOR2;IGF1R;TBX2;NC
OA3;TBX1 
positive regulation of 
vasodilation 
3 27 11% 5.56E-04 GO:0045909 APLN;EGFR;PTPRM 
retina development in camera-
type eye 
8 113 7% 5.85E-04 GO:0060041 SKI;PDGFRB;CHD7;PAX2;
DRD4;MDM1;PRPH;PTPR
M 
positive regulation of ion 
transmembrane transport 
3 24 13% 6.40E-04 GO:0034767 PDGFRB;KCNE1;ERG 
sympathetic nervous system 
development 
3 24 13% 6.68E-04 GO:0048485 NTRK1;SEMA3F;GATA3 
multicellular organismal 
movement 
3 27 11% 7.38E-04 GO:0050879 TNNI2;ATP8A2;CACNA1A 
regulation of reactive oxygen 
species metabolic process 
5 64 8% 8.79E-04 GO:2000377 PDGFRB;EGFR;RAC1;PAX2
;NOX4 
regulation of interleukin-2 
production 
4 45 9% 8.88E-04 GO:0032663 PDE4D;TRIM27;CARD11;G
ATA3 
negative regulation of 
osteoblast differentiation 
4 34 12% 8.97E-04 GO:0045668 SKI;HDAC4;CDK6;NOTCH1 
homeostatic process 38 1087 3% 9.89E-04 GO:0042592 PPOX;NCSTN;ABCG5;KNG
1;TERT;PDGFRB;COL11A2;
TAP2;BTBD9;POLD2;EGFR
;RAC1;SLC26A4;FIS1;ANK1
;ATP6V1H;TERF1;DFNB31;
TCF7L2;GATA3;PAX2;DRD
4;NOX4;RIC3;NCOR2;AACS
;SLC24A4;TRPM1;FAM82A2
;NARFL;SLC9A5;RPH3AL;C
CL3;CACNA1A;SLC12A5;ER
G;TXNRD2;TXN2 
head development 5 53 9% 1.21E-03 GO:0060322 SKI;GLI2;CHD7;TCF7L2;TB
X1 
pancreas development 6 80 8% 1.21E-03 GO:0031016 CDK6;TCF7L2;PAX2;ONEC
UT1;IGF1R;MEIS2 
membrane depolarization 6 73 8% 1.29E-03 GO:0051899 PRKCZ;PPOX;DRD4;SEZ6;
CACNA1A;ERG 
epithelial cell morphogenesis 4 39 10% 1.41E-03 GO:0003382 RAC1;GATA3;PAX2;FRMD6 
regulation of calcium ion-
dependent exocytosis 
3 27 11% 1.47E-03 GO:0017158 NOTCH1;RPH3AL;CACNA1
A 
prostate gland epithelium 
morphogenesis 
3 26 12% 1.55E-03 GO:0060740 GLI2;NOTCH1;IGF1R 
anatomical structure maturation 4 46 9% 1.58E-03 GO:0071695 NOTCH1;GATA3;PAX2;CAC
NA1A 
chloride transmembrane 
transport 
4 48 8% 1.91E-03 GO:1902476 CLCN5;SLC26A4;ANO1;SLC
12A5 
lung epithelial cell 
differentiation 
3 27 11% 2.28E-03 GO:0060487 CREB1;FOXP4;NCOR2 
heart valve development 3 27 11% 2.40E-03 GO:0003170 SHOX2;NOTCH1;GATA3 
long-term memory 3 27 11% 2.44E-03 GO:0007616 PRKCZ;BTBD9;SGK1 
positive regulation of 
multicellular organism growth 
3 32 9% 2.61E-03 GO:0040018 CREB1;CHD7;ATP8A2 
protein N-linked glycosylation 6 103 6% 2.66E-03 GO:0006487 SEC31A;PGM3;VCP;MGAT5
B;KCNE1;ALG12 
protein trimerization 3 32 9% 3.15E-03 GO:0070206 SKI;TRIM27;C1QTNF1 
adult locomotory behavior 6 86 7% 3.31E-03 GO:0008344 TRH;BTBD9;CHD7;DRD4;S
EZ6;CACNA1A 
regulation of skeletal muscle 
tissue development 
5 61 8% 3.46E-03 GO:0048641 HDAC4;SHOX2;NOTCH1;T
CF7L2;TBX1 
cell fate determination 4 43 9% 3.56E-03 GO:0001709 LBX1;GATA3;PAX2;TBX2 
cellular protein complex 
assembly 
11 235 5% 4.03E-03 GO:0043623 TUBA4A;TUBB;RAC1;PTK2;
GSN;CALY;NRG3;PICALM;
RIC3;COG4;CCT6B 
porphyrin-containing compound 
metabolic process 
3 41 7% 7.56E-03 GO:0006778 PPOX;ANK1;CYP1A2 
G2/M transition of mitotic cell 
cycle 
7 133 5% 9.13E-03 GO:0000086 TUBA4A;TUBB;DLC1;TERF
1;DCTN3;WEE1;NDE1 
Cellular components             
vesicle coat 4 40 10% 1.80E-04 GO:0030120 COPA;SEC31A;EGFR;PICA
LM 
dendritic shaft 4 35 11% 2.91E-04 GO:0043198 CNIH3;SYNGAP1;SEZ6;SLC
12A5 
apical part of cell 14 313 4% 2.17E-03 GO:0045177 CLCN5;PRKCZ;ABCG5;AM
OTL2;PDE4D;PDGFRB;EG
FR;SLC26A4;PTK2;EPB41L
4B;SHANK2;NOX4;MYL12B;
KCNE1 
chromosomal part 23 600 4% 2.62E-03 GO:0044427 DNMT3A;CREB1;TERT;C6o
rf167;ORC3L;HUS1B;MAD1
L1;POLD2;DLC1;TERF1;VC
P;DCTN3;TCF7L2;GATA3;R
NF169;NCOR2;PDS5B;SNW
1;USP3;BUB1B;NDE1;HLCS
;RANGAP1 
nuclear matrix 6 95 6% 8.78E-03 GO:0016363 PRKCZ;DNMT3A;NCOR2;S
NW1;HLCS;PHF5A 
Molecular functions             
transmembrane receptor protein 
tyrosine kinase activity 
8 67 12% 3.34E-07 GO:0004714 NTRK1;INSRR;ROR1;EPHA
8;PDGFRB;TRIM27;EGFR;I
GF1R 
insulin receptor substrate 
binding 
3 13 23% 1.31E-06 GO:0043560 INSRR;PRKCZ;IGF1R 
peptide hormone receptor 
binding 
3 16 19% 1.48E-06 GO:0051428 GNAO1;RUNDC3A;PSMC5 
neuropeptide receptor binding 3 23 13% 8.42E-05 GO:0071855 APLN;PPOX;GNAO1 
proteoglycan binding 3 21 14% 1.82E-04 GO:0043394 SEMA5A;COL5A1;SLIT1 
structural constituent of 
cytoskeleton 
7 91 8% 1.98E-04 GO:0005200 TUBA4A;TUBA4B;TUBB;AN
K1;TLN1;EPB41L4B;ANK3 
protein kinase C activity 3 20 15% 2.03E-04 GO:0004697 PRKCZ;PRKCH;CCL3 
retrograde vesicle-mediated 
transport  
3 24 13% 3.48E-04 GO:0006890 RER1;COPA;COG4 
potassium channel regulator 
activity 
4 37 11% 3.62E-04 GO:0015459 PRKCZ;SGK1;DRD4;KCNE1 
phosphatidylinositol 3-kinase 
binding 
3 23 13% 4.68E-04 GO:0043548 INSRR;PDGFRB;IGF1R 
iron-sulfur cluster binding 5 64 8% 4.74E-04 GO:0051536 RFESD;TYW1B;FDX1;NARF
L;ACO2 
metal cluster binding 5 64 8% 4.74E-04 GO:0051540 RFESD;TYW1B;FDX1;NARF
L;ACO2 
carboxy-lyase activity 3 35 9% 2.57E-03 GO:0016831 UXS1;ME3;PPCDC 
Table S2. Functional characterization of DRD4 CpG loci 
  CpG information   ENCODE Regulatory Elementsa 
CpG Genomic 
location 
Proximity to 
CpG island 
Position Std B P-value Mean SD   TF Histone DNAase I 
                    
cg07212818 Body Island 638076 -0.42 2.16E-06 0.41 0.08   Y Y Y 
cg05717871 Body Island 638507 -0.42 2.23E-06 0.59 0.13   Y Y Y 
cg03909863 Body Island 638404 -0.42 2.29E-06 0.87 0.11   Y Y Y 
cg11335335 Body Island 637885 -0.40 5.63E-06 0.44 0.12   Y Y Y 
cg01616529 Body Island 638424 -0.40 8.43E-06 0.52 0.13   Y Y Y 
cg09386376 Body Island 638939 -0.32 3.57E-04 0.65 0.11   Y Y Y 
cg14433983 TSS1500 Island 636460 -0.30 7.72E-04 0.71 0.08   N Y N 
cg06299284 TSS1500 Island 636659 -0.26 3.70E-03 0.39 0.12   Y Y N 
cg03855291 Body Island 639423 -0.26 4.13E-03 0.48 0.12   Y Y Y 
cg06825142 TSS200 Island 637170 -0.23 0.01 0.09 0.02   Y Y Y 
cg23501406 TSS1500 Island 637035 -0.20 0.03 0.06 0.02   Y Y N 
cg16029939 Body Island 640328 -0.18 0.05 0.40 0.12   Y Y Y 
cg12928379 TSS200 Island 637175 0.14 0.13 0.07 0.01   Y Y Y 
cg00556112 TSS200 Island 637173 -0.14 0.14 0.12 0.02   Y Y Y 
cg02762115 Body Island 640446 0.11 0.26 0.55 0.11   Y Y Y 
cg08726248 TSS1500 Island 637032 -0.10 0.27 0.06 0.01   Y Y Y 
cg20931042 TSS200 Island 637162 -0.09 0.34 0.08 0.01   Y Y Y 
cg09607276 1stExon Island 637491 -0.08 0.37 0.07 0.03   Y Y N 
cg23231692 TSS1500 N_Shore 636167 0.07 0.46 0.84 0.03   N Y N 
cg15861585 TSS1500 Island 637038 -0.03 0.78 0.07 0.02   Y Y N 
cg20411756 3'UTR Island 640606 0.00 0.98 0.72 0.13   Y Y Y 
 
a
 Overlap between each CpG site annotated to the DRD4 gene and regulatory elements based on ENCODE data, including (i) transcription factors (data 
generated on 161 transcription factors in 91 cell types via ChIP-seq), (ii) histone marks (only relevant cell lines examined, including blood [GM12878], and 
umbilical vein endothelial [HUVEC] cells), and (iii) DNase I hypersensitivity clusters (based on data from 125 cell types). Y indicates that the CpG site 
coincides with the regulatory element, whereas N indicates no overlap.    
 
 
 
 
 
 
 
Table S2. Cont’d 
  Saliva-blood concordance 
(Smith et al., 2014)b 
  Blood-CNS concordance 1                                                                                                                                                                            
(Hannon et al., 2015)c 
CpG T P-value   correlation   
>1 region 
PFC   STG    EC   CER 
        r P-value   r P-value   r P-value   r P-value 
cg07212818 10.38 2.07E-13   Y 0.69 6.93E-12   0.71 1.03E-12   0.60 2.53E-08   0.39 8.06E-04 
cg05717871 11.44 1.24E-14   Y 0.49 8.35E-06   0.49 7.25E-06   0.52 4.08E-06   0.16 0.19 
cg03909863 9.70 1.69E-12   Y 0.54 7.82E-07   0.60 1.37E-08   0.51 5.97E-06   0.13 0.30 
cg11335335 7.15 7.00E-09   Y 0.68 2.92E-11   0.46 5.36E-05   0.62 2.82E-09   0.44 1.38E-04 
cg01616529 9.10 1.13E-11   Y 0.64 1.08E-09   0.65 3.85E-10   0.70 3.88E-11   0.21 0.08 
cg09386376 7.34 3.58E-09   Y 0.53 1.41E-06   0.57 9.26E-08   0.47 3.36E-05   0.36 0.03 
cg14433983 14.44 2.62E-18   Y 0.49 7.79E-06   0.68 1.89E-11   0.67 1.64E-10   0.17 0.16 
cg06299284 16.72 1.10E-20   Y 0.40 4.05E-04   0.54 4.72E-07   0.55 9.16E-07   0.16 0.17 
cg03855291 7.01 1.12E-08   Y 0.28 0.02   0.48 1.30E-05   0.42 2.42E-04   0.34 3.96E-03 
cg06825142 0.37 0.71   N -0.16 0.17   0.10 0.39   -0.08 0.48   0.15 0.20 
cg23501406 3.00 4.40E-03   N -0.02 0.85   0.15 0.19   0.15 0.21   0.02 0.84 
cg16029939 1.56 0.13   Y 0.39 6.01E-04   0.40 4.46E-04   0.34 3.60E-03   0.37 1.75E-03 
cg12928379 0.32 0.75   Y 0.20 0.10   0.31 0.01   0.08 0.52   0.12 0.33 
cg00556112 1.41 0.16   N 0.00 0.99   -0.01 0.93  -0.18 0.14   -0.14 0.26 
cg02762115 -0.01 0.99   N 0.14 0.22   0.11 0.36   -0.03 0.84   0.06 0.61 
cg08726248 2.67 0.01   N -0.06 0.60   0.18 0.13   0.26 0.03   0.07 0.59 
cg20931042 1.47 0.15   N -0.15 0.17   0.03 0.80   0.01 0.92   0.30 0.01 
cg09607276 3.82 4.15E-04   N 0.19 0.11   0.21 0.07   0.09 0.45   0.07 0.54 
cg23231692 11.32 1.29E-14   N 0.09 0.44   -0.01 0.93   0.11 0.36   -0.05 0.67 
cg15861585 1.95 0.06   N 0.05 0.68   0.12 0.30   0.06 0.61   0.19 0.12 
cg20411756 1.32 0.20   N 0.17 0.14   0.10 0.38   0.17 0.15   0.17 0.17 
 
b 
Results extracted from Supplementary Table S1 of Smith et al (2014). T-values and associated p-values represent the output of regression models that were 
run for each CpG site in the Illumina 450k array, with DNAm levels in saliva entered as the predictor variable and DNAm levels in whole blood as the outcome 
variable, adjusting for technical covariates and proportion of epithelial cells in each sample.          
      
c
 Results extracted from Hannon et al (2015), showing for each CpG site the correlation between DNAm levels in peripheral blood and that of CNS tissue 
across four brain regions (PFC: prefrontal cortex; STG: superior temporal gyrus; EC: entorhinal cortex; CER: cerebellum).  For legibility, we also indicate 
whether each CpG shows significant blood-CNS concordence with at least one brain region, whereby Y indicates yes, and N indicates no.  
                     
    
    
   
Table S2. Cont’d 
  Blood-CNS concordance 2 (Edgar et al., 2017)d   Association with mQTL (Gaunt et al., 2016)e 
CpG BA10   BA20   BA7   Total Brain   Total Brain    Cis/     
Trans 
N SNP ID 
  r   r   r   r   %       
cg07212818 0.36   0.43   0.44   0.41   90%   Cis 11 rs150403728, rs35482931, rs61877858, rs79915070, rs138188226, 
rs202011316, rs2740373, rs6421975, rs72841224, rs72844713, rs72844728 
cg05717871 0.58   0.61   0.60   0.60   90%   -   - 
cg03909863 0.45   0.60   0.41   0.49   90%   -   - 
cg11335335 0.13   0.38   -0.06   0.15   50-75%   Cis 2 rs150403728, rs2740373 
cg01616529 0.62   0.71   0.80   0.71   90%   Cis 6 rs150403728, rs112888889, rs72844713, rs61877858, rs2740373, 
rs61876662  
cg09386376 0.39   0.29   0.26   0.31   75-90%   Cis 7 rs138188226, rs150403728, rs150403728, rs11246235, rs936472, 
rs112888889, rs72844710 
cg14433983 0.26   0.29   0.11   0.22   50-75%   -   - 
cg06299284 0.30   0.51   0.52   0.44   90%   Cis 5 rs2740375, rs7116535, rs10902196, rs7928305, rs936472 
cg03855291 0.60   -0.01   0.35   0.31   75-90%   Cis 4 rs150403728, rs11246235, rs7124601, rs936472 
cg06825142 0.39   0.10   0.12   0.20   50-75%   -   - 
cg23501406 -0.04   0.08   0.10   0.05   <50%   -   - 
cg16029939 0.35   0.07   0.01   0.14   50-75%   -   - 
cg12928379 0.19   0.35   0.37   0.30   75-90%   -   - 
cg00556112 0.15   0.25  0.24   0.21   50-75%   -   - 
cg02762115 0.13   -0.35   -0.10   -0.11   -   Cis 4 rs150403728, rs117429558, rs936472, rs55771159 
cg08726248 0.24   0.12   0.16   0.17   50-75%         
cg20931042 -0.18   -0.12   0.14   -0.05   -   -   - 
cg09607276 0.07   0.01   -0.11   -0.01   -   -   - 
cg23231692 -0.34   0.11   0.04   -0.06   -   -   - 
cg15861585 0.45   0.11   -0.10   0.15   50-75%   -   - 
cg20411756 0.09   0.25   -0.13   0.07   <50%   Cis 1 rs117429558 
 
d
 Results extracted from Edgar et al (2017), showing for each CpG site the correlation between DNAm levels in peripheral blood and that of CNS tissue across 
three brain regions (BA10: anterior-most portion of the prefrontal cortex; BA20: inferior temporal area; BA7: parietal cortex), as well as total brain (mean of 
these three regions). Effect sizes were extracted from the BECon online tool. Due to small sample size (n = 15), no p-values are provided. Instead, the ranking 
of each CpG site in terms of strength of blood-brain concordance is reported (as a percentile). 
e 
Association between each CpG site and genetic mQTLs, based on GCTA analysis results extracted from the mQTLdb resource (Gaunt et al., 2016). 
Information includes whether the mQTL is cis (i.e. SNP within ±1000 base pairs of the DNAm site) or trans (i.e. ±1 million base pairs), the number of mQTLs 
associated with the CpG site and their SNP IDs (bolded if shown to associate with the CpG site at > 1 time point). The underlined SNP ID indicates the mQTL 
that was used in the Mendelian randomisation analysis (rs2740373).  
Table S3. Sensitivity analyses of DRD4 CpG loci 
  CpG information   Original                        
analysisa 
Sensitivity                       
analysis 1b:              
Winsorized data 
Sensitivity            
analysis 2c:                  
SVA correction 
 Sensitivity            
analysis 3d:                  
Subsample with buccal 
cells as predicted tissue 
 Sensitivity            
analysis 4e:                  
Binary fights variable 
CpG ID Genomic 
location 
Proximity to 
CpG island 
Position   T P-value   T P-value   T P-value  T P-value  T P-value 
                               
cg07212818 Body Island 638076   -4.99 2.16E-06   -4.99 2.16E-06   -4.32 3.53E-05  -4,53 1,78E-05  -4.00 1.11E-04 
cg05717871 Body Island 638507   -4.98 2.23E-06   -4.98 2.23E-06   -5.02 2.04E-06  -4,27 4,68E-05  -4.13 6.72E-05 
cg03909863 Body Island 638404   -4.97 2.29E-06   -4.80 4.79E-06   -4.49 1.81E-05  -4,45 2,38E-05  -4.36 2.77E-05 
cg11335335 Body Island 637885   -4.76 5.63E-06   -4.76 5.63E-06   -4.09 8.51E-05  -4,33 3,85E-05  -4.18 5.74E-05 
cg01616529 Body Island 638424   -4.66 8.43E-06   -4.66 8.43E-06   -4.29 3.96E-05  -4,17 6,78E-05  -3.60 4.63E-04 
cg09386376 Body Island 638939   -3.68 3.57E-04   -3.68 3.57E-04   -3.79 2.53E-04  -3,09 2,63E-03  -3.30 1.27E-03 
cg14433983 TSS1500 Island 636460   -3.45 7.72E-04   -3.46 7.59E-04   -3.41 9.16E-04  -3,59 5,25E-04  -2.73 7.32E-03 
cg06299284 TSS1500 Island 636659   -2.96 3.70E-03   -2.96 3.70E-03   -2.16 0.03  -2,92 4,34E-03  -2.61 0.01 
cg03855291 Body Island 639423   -2.93 4.13E-03   -2.93 4.13E-03   -2.87 4.90E-03  -2,49 0,01  -2.31 0.02 
cg06825142 TSS200 Island 637170   -2.53 0.01   -2.68 0.01   -1.19 0.24  -2,30 0,02  -2.91 4.31E-03 
cg23501406 TSS1500 Island 637035   -2.18 0.03   -2.22 0.03   -1.49 0.14  -2,62 0,01  -1.88 0.06 
cg16029939 Body Island 640328   -1.99 0.05   -1.99 0.05   -1.84 0.07  -1,95 0,05  -2.37 0.02 
cg12928379 TSS200 Island 637175   1.53 0.13   -1.52 0.13   0.15 0.88  1,66 0,10  1.73 0.09 
cg00556112 TSS200 Island 637173   -1.49 0.14   1.51 0.13   -0.05 0.96  -1,19 0,24  -2.33 0.02 
cg02762115 Body Island 640446   1.14 0.26   1.14 0.26   2.19 0.03  1,39 0,17  0.13 0.90 
cg08726248 TSS1500 Island 637032   -1.12 0.27   -1.10 0.27   -1.10 0.27  -1,57 0,12  -0.51 0.61 
cg20931042 TSS200 Island 637162   -0.96 0.34   -0.90 0.37   0.50 0.62  -0,99 0,33  -0.34 0.74 
cg09607276 1stExon Island 637491   -0.90 0.37   -0.81 0.42   -0.74 0.46  -0,88 0,38  -0.57 0.57 
cg23231692 TSS1500 N_Shore 636167   0.74 0.46   0.68 0.50   0.09 0.93  0,99 0,32  0.01 0.99 
cg15861585 TSS1500 Island 637038   -0.28 0.78   -0.12 0.91   -0.53 0.60  -0,16 0,87  -0.49 0.62 
cg20411756 3'UTR Island 640606   0.03 0.98   0.03 0.98   0.64 0.53  0,16 0,87  -0.96 0.34 
N.b. all analyses control for age, sex and ethnicity 
a
 Results from the original analysis, associating non-winsorised DNA methylation values and engagement in physical fights (4-level ordinal variable, spanning 0-5+ times in the past year)  
b
 Results from the first sensitivity analysis, associating winsorized DNA methylation values (threshold: 3*IQR) and engagement in physical fights. 
c
 Results from the second sensitivity analysis, associating non-winsorized DNA methylation values and engagements in physical fights, additionally controlling for ten surrogate variables to 
minimize the potential influence of unwanted confounders. 
d
 Results from the third sensitivity analysis, associating non-winsorized DNA methylation values and engagements in physical fights only in the subsample of participants with 'buccal' as 
predicted tissue, based on the Horvath algorithm (Horvath et al., 2013). 
e
 Results from the fourth sensitivity analysis, associating non-winsorized DNA methylation values with a collapsed variable of engagements in physical fights (2-level binary variable, 0 = no 
fights, 1 = any number of fights)
Table S4. Cross-tissue correspondence in DRD4 methylation 
 
    Strength of association 
with fights                        
(discovery sample) 
  Saliva-Blood 
correspondence 
(Smith et al., 2014) 
  Blood-CNS correspondence 1                                                        
(Hannon et al., 2015) 
Blood-CNS correspondence 2                                                      
(Edgar et al., 2017) 
            PFC   STG   EC   CER BA10   BA20   BA7   
Strength of association with fights                    r -                                 
p                                   
                                      
Saliva-Blood correspondence                r 0.59   -                             
p 0.01                                 
                                      
Blood-CNS correspondence 1:                                      
                    PFC r 0.69   0.65   -                         
p 1.00E-03   0.001                             
                                      
                    STG r 0.77   0.69   0.90                         
p 5.40E-05   0.001   3.61E-08   -                     
                                      
                    EC r 0.77   0.77   0.89   0.93                     
p 4.90E-05   4.40E-05   8.13E-08   2.11E-09   -                 
                                      
                    CER r 0.49   0.15   0.55   0.55   0.57   -             
p 0.02   0.52   0.01   0.01   0.01                 
Blood-CNS correspondence 2:                                      
                    BA10 r 0.34   0.34   0.53   0.47   0.34   -0.01 -           
p 0.13   0.13   0.01   0.03   0.13   0.96             
                                      
                    BA20 r 0.54   0.17   0.26   0.44   0.28   0.02 0.49   -       
p 0.01   0.47   0.25   0.05   0.21   0.93 0.03           
                                      
                    BA7 r 0.54   0.25   0.31   0.38   0.25   0.03 0.73   0.56   -   
p 0.01   0.27   0.17   0.09   0.27   0.89 1.85E-04   0.01       
                                      
                    Brain (Mean) 
 
r 0.55   0.30   0.44   0.50   0.35   0.02 0.87   0.79   0.90   
p 0.01   0.18   0.05   0.02   0.13   0.94 2.77E-07   2.05E-05   3.22E-08   
 
This table shows how indices of correspondence extracted from the three cross-tissue resources used in our study (Smith et al., 2014; Hannon et al, 2015; Edgar et al., 2017) relate to our 
findings and to one another, based on data from all DRD4 methylation sites (21 CpGs). From this table, two key findings emerge. First, there is a significant correlation between how strongly 
DRD4 sites associate with physical aggression in our sample and how much cross-tissue concordance they show across all three resources. In other words, DRD4 sites that showed stronger 
associations with physical aggression, also showed stronger cross-tissue concordance in saliva, blood and brain. Second, brain regions that are anatomically most comparable across resources 
(e.g. Hannon’s prefrontal cortex and Edgar’s BA10) also show the strongest convergence with one another.
Figure S1. Visualization of probe-level EWAS results 
Figure S2. Bias- and inflation-corrected  EWAS results using the Bacon R package 
 
 
The results from the Bacon analysis indicated minimal bias and inflation in out probe-specific EWAS 
(Bayesian estimates of bias = .049; Bayesian inflation factor = 1.023). This is also visually represented in 
the histogram (A), which indicates only a very small bias towards the right (red line) as well as the QQ plot 
(B), which shows minimal change after correction. (C) shows the top 30 CpG loci from our EWAS, with the 
addition of bacon-corrected p-values. All associations became stronger after correction (including all sites in 
our DRD4 DMR, showed in bold), indicating that potentially confounding effects biased our initial effects 
towards the null.
Figure S3. Scatterplots of the five DRD 4CpG sites contained in the genome-wide significant DMR 
 
Figure S4. PCA analysis of the 5 CpG sites contained in the DRD4 DMR (R princomp package) 
 
    Figure S5. DRD4 methylation and expression across peripheral and central nervous system (CNS) tissue 
 
Figure S6. Mendelian randomization analysis 
 
 
 
A. Schematic representation of the MR variable assumptions, including that (i) the genetic instrument (i.e. DRD4 SNP) should have an effect on methylation levels (solid line), and (ii) that the genetic instrument 
should not be associated with the outcome (only through the risk factor, i.e. DNAm) or other correlated factors (i.e. confounders; dotted line)  
B. B. Results of the MR analysis, including (i) the mQTLdb output identifying a genetic instrument for DRD4 methylation within our genome-wide significant DMR; (ii) the summary statistics for the genetic 
instrument, based on the EAGLE Consortium GWAS on physical aggression; and (iii) the results of the MR analysis, which was run using the TwoSampleMR package in R, available as part of the MR-Base 
platform.                     
        
                    
        
                    
                    
              
                     
       
